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CRISPR-Cas systems endow bacteria and archaea with adaptive 
immunity against foreign genetic threats, like phages and plasmids. These 
immune systems are comprised of CRISPR-associated (Cas) protein effectors 
and DNA-based storage of immunological memories in the CRISPR array. The 
CRISPR array is a series of direct repeats intercalated by variable spacer 
sequences (~30bp) of foreign origin. Upon infection, spacers are excised from 
the foreign genome and integrated into the array. The array is then transcribed 
and parsed into individual CRISPR RNAs, each containing a single spacer 
sequence, which are used by Cas nucleases to identify foreign nucleic acids for 
destruction. Thus, spacer sequences represent molecular memories that serve to 
define the specificity of the CRISPR immune response. 
New spacers are added invariably to the 5’ end of the array; therefore, the 
first spacer matches the most recent foreign invader. How this order is 
established and whether this highly polarized order of spacer insertion influences 
CRISPR-Cas immunity has not been explored. In my thesis work, I showed that 
conserved nucleotides within the leader, a sequence located immediately 
upstream of the CRISPR array, specify the site of new spacer integration with 
high fidelity. Mutation of this sequence results in erroneous incorporation of new 
spacers into the middle of the array. To interrogate the importance of polarized 
spacer addition, I compared the immune responses generated by CRISPR 
systems containing wild type and mutant leader sequences. I showed that 
spacers added through polarized acquisition give rise to more robust immunity 
than spacers added to the middle of the array. This demonstrated that the 
CRISPR-Cas system specifies the site of spacer integration to optimize the 
immune response against the latest and most immediate threat to the host. 
Because addition of new spacers pushes existing spacers further 
downstream, each spacer added to the CRISPR array weakens the immunity 
provided by already existing spacers within the array. How CRISPR systems 
address this conundrum had not been explored. In this thesis work, I showed that 
CRISPR systems exhibit significant natural variation in the rates of spacer 
acquisition and thereby can modulate the lifespan of existing spacers in the 
array. Fast-adapting systems can respond quickly to new invaders, but existing 
spacers rapidly lose their potency. In contrast, slow-adapting systems preserve 
potency of existing spacers at the cost of reduced rates of spacer acquisition. I 
showed that bacteria have overcome these tradeoffs by harboring multiple 
CRISPR systems that acquire new spacers at different rates. I also found that 
leader-repeat junctions serve as a means for spacer acquisition complexes to 
discriminate between related CRISPR arrays. I propose a model whereby 
bacteria can harbor two related CRISPR systems as a means to form both short- 
and long-term immunological memories against foreign invaders. 
Bacteria were once thought to possess only primitive forms of innate 
immunity, but this notion was turned on its head by the discovery of the CRISPR-
Cas immune system. My thesis work has revealed a deeper complexity of 
bacterial immunity and evolution by demonstrating that CRISPR systems 
functionally organize molecular memories of past invaders as a means to confer 
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CHAPTER 1: INTRODUCTION TO THE CRISPR-CAS IMMUNE RESPONSE 
1.1 INTRODUCTION 
Prokaryotic organisms are frequently exposed to both beneficial and 
parasitic foreign nucleic acids1. On one hand, this allows organisms to access 
and incorporate diverse genetic material, like antibiotic resistance genes 
encoded on plasmids or virulence factors encoded by temperate phages. On the 
other, this renders cells vulnerable to parasitic elements that compromise the 
fitness of the population, like plasmid-encoded transposons or virulent phages. 
To balance these costs and benefits, bacteria and archaea have evolved a 
number of pathways to curate the nucleic acids entering the cell. These 
pathways have profound implications for the evolution of prokaryotic 
populations1. 
Clustered regularly interspaced short palindromic repeats (CRISPR) and 
their associated genes (cas) encode one such mechanism by which cells restrict 
incoming nucleic acids2,3. CRISPR-Cas systems have the unique ability to 
heritably alter the host genome by incorporating small fragments of foreign 
nucleic acids, known as spacers, in between the repeats of the CRISPR locus 
(Figure 1.1.1)2. This process is known as spacer acquisition 4-6. Spacers are 
transcribed and parsed into individual CRISPR RNAs (crRNAs), which guide 
effector Cas nucleases to cleave cognate nucleic acids. Thus, spacer sequences 
define the specificity of the CRISPR-Cas immune response, bestowing immunity 





Figure 1.1.1. General schematic of the spacer integration reaction.  
The CRISPR array comprises a series of direct, semi-palindromic repeats 
intercalated with variable spacer sequences of foreign origin. The array is 
preceded by an AT-rich leader sequence. Integration of new spacers begins with 
a concerted cleavage–ligation reaction that occurs preferentially at the leader end 
of the first repeat, whereby the terminal 3′-OH of the protospacer carries out a 
nucleophilic attack. Next, the repeat DNA is bent, and a second cleavage–ligation 
reaction takes place at the spacer side of the repeat. The product of this reaction 
is an intermediate in which the 3′ ends of a double-stranded (dsDNA) 
protospacer are ligated to single-stranded DNA (ssDNA) repeat sequences. The 
ssDNA repeats are presumably filled by DNA polymerase and ligated to complete 
the spacer integration process. 
 
Found in approximately 45% of bacteria and 85% of archaea, CRISPR 
systems have been categorized by cas gene content into 2 classes, 6 types, and 
	 3 
over 20 subtypes7. Each of the six types utilizes functionally distinct effector 
complexes that mediate the destruction of foreign nucleic acids. Whereas Types 
I, II, and V target DNA, Type VI targets RNA, and Type III targets both RNA and 
DNA (Type IV systems have not been experimentally characterized yet)7. In 
contrast, the core machinery that mediates spacer acquisition, encoded primarily 
by cas1 and cas2, is relatively well conserved across the different types. Spacer 
acquisition can be conceptually divided into two phases: protospacer capture and 
spacer integration. During the first phase, protospacers (spacer sequences in the 
invading genome) must be selected and extracted from foreign genomes. In the 
second phase, spacers must undergo processing and incorporation into the 
CRISPR locus. Recent studies have revealed several aspects of the molecular 
mechanism of spacer acquisition and how these correlate with the specific 
targeting mechanism of each different CRISPR Type. Here, we review the 
current models of spacer acquisition and discuss the future of the field, both in 
terms of basic science research and technological applications. 
1.2 INTEGRATION OF NEW SPACERS 
The Cas1-Cas2 integrase 
The Cas1-Cas2 complex is the core machinery that mediates spacer 
acquisition. Cas1 is the most highly conserved Cas protein and can be found in 
all six CRISPR Types7. It is believed that Cas1 evolved as the core enzyme of a 
class of transposons called casposons and was eventually co-opted to form the 
basis of the CRISPR-Cas immune system8. In the context of CRISPR immunity, 
Cas1 interacts with Cas2 to form a complex that acts as the spacer integrase9-13. 
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This heterohexameric complex [(Cas12-Cas2)2] contains two separate DNA-
binding regions, one that binds the incoming protospacer and one that binds the 
CRISPR array. Once loaded with the incoming spacer, the Cas1-Cas2 complex 
catalyzes two cleavage-ligation reactions, first at the leader-end of the first repeat 
of the CRISPR array and subsequently at the spacer-end of the repeat12-14 
(Figure 1.1.1). In this reaction, the terminal 3’-OH of each strand of the 
protospacer DNA performs a nucleophilic attack on each end of the repeat DNA. 
The product of this reaction is an intermediate in which the 3’ ends of a dsDNA 
protospacer is ligated to ssDNA repeat sequences. These ssDNA “gaps” are 
presumably filled by a DNA polymerase and then ligated, resulting in a 
simultaneous spacer insertion and repeat duplication12-18. 
Site-specific integration of new spacers 
The integration of new spacers by Cas1-Cas2 is polarized, meaning that 
new spacers are predominantly added to the leader-end of the CRISPR array. 
For this reason CRISPR loci have been compared to molecular fossil records of 
past infections, with the newest memories at the leader-end and the most 
ancestral spacer sequences at the trailer-end 18. By ordering spacers 
chronologically, CRISPR systems optimize their immune response against the 
most recent invaders since leader-end spacers provide more robust immunity 
relative to more downstream positions19. This has been proposed to be a bet-
hedging strategy in which resources are prioritized to defend the host against the 
most recent invader, which is also most likely to be the biggest threat to the 
cell19,20. One potential mechanism underlying this phenomenon is the differential 
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expression of crRNAs across the CRISPR array, which has been observed in 
many CRISPR Types21-25. In one study of the Streptococcus pyogenes Type II-A 
system, a two-fold difference was observed when comparing the abundance of 
crRNAs originating from the same spacer sequence in the first or fifth position in 
the array19. Given that a single Cas9 ribonucleoprotein can take hours to find its 
target (according to single-molecule experiments)26 and that it is reported to be a 
single-turnover enzyme27, it is possible that modest differences in crRNA 
abundance can give rise to larger differences in the level of immunity afforded to 
the host 19.  
Several mechanisms have the potential to “re-activate” ancestral 
memories that are positioned further downstream in the CRISPR array. Spacer 
deletions have been frequently observed in laboratory and natural contexts 28,29. 
Indeed, in one study of the Type II-A system from S. pyogenes, deletion of four 
spacers from the 5’ end of the array was heavily selected for during phage 
infection, which enabled a spacer in position 5 to be shifted to position 1 to 
enable maximum levels of immunity 19. Alternatively, another study revealed that 
internal promoters contained within spacer sequences can enable high 
expression of downstream crRNAs 30. In addition, we speculate that is possible 
that lower expression of downstream crRNAs that are unable to provide full 
immunity could enable a primed immune response (see Primed Spacer 
Acquisition section). 
How this polarized addition of new spacers is achieved differs by CRISPR 
Type (Figure 1.1.2). In Type I CRISPR systems, an α-helix of Cas1 makes 
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sequence-specific contacts with the minor groove of the leader12,31, but this is not 
sufficient to enforce leader-end spacer addition15. Rather, factors encoded by the 
host genome are required for site-specific integration. In Types I-E and I-F, a 
protein called Integration Host Factor (IHF) is required for polarized spacer 
integration in vitro and is required for spacer acquisition in vivo. These Type I 
leaders contain a conserved IHF binding site, and binding of this site by IHF 
induces a topological change of the CRISPR array DNA. This creates the ideal 
target substrate for the Cas1-Cas2 integrase specifically at the first repeat12,32. 
Additionally, the Cas1-Cas2 integrase makes contacts with IHF as well as 
upstream sequences in the leader as a result of DNA bending induced by IHF12 
(Figure 1.1.2, top). This mechanism leads to a conundrum for Type I CRISPR 
systems found in Gram-positive bacteria, which lack IHF homologs32. It is 
possible that related DNA-bending proteins (i.e. HU or H-NS) could fulfill this role. 
Indeed, an archaeal Type I-A system, whose host lacks IHF, exhibits leader 
specificity for spacer integration in a manner dependent on as of yet unidentified 
host factor(s) 33. 
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Figure 1.1.2. Two mechanisms for preferential spacer acquisition at the 
leader end of the CRISPR array.  
In the type I system, integration host factor (IHF) binds to a conserved binding 
site in the leader and induces DNA bending, which enables the Cas1–Cas2 
complex to perform the first cleavage–ligation reaction. Cas1–Cas2 makes 
specific contacts with upstream and downstream sequences in the leader, as well 
as with IHF. In the type II system, Cas1-mediated recognition of the leader 




Type II CRISPR systems, which are commonly found in Gram-positive 
hosts34, also exhibit strictly polarized spacer integration2,14,19,35. In contrast to the 
Type I machinery, the Type II Cas1-Cas2 complex can induce the necessary 
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DNA topology for the spacer integration reaction without any additional host 
factors13,14. Similar to the Type I system, an α-helix of the Type II Cas1 makes 
sequence-specific contacts with the minor groove of the leader DNA (for Type II, 
this is termed the Leader Anchoring Sequence, “LAS”)13,14,19. In contrast to Type 
I, these contacts are sufficient to enforce leader-end spacer integration without 
the need of any additional host factors (Figure 1.1.2, bottom)13,14,19. These 
additional contacts between the LAS and Cas1 improve the kinetics of the 
cleavage-ligation reaction at the leader-repeat junction, enforcing polarized 
spacer addition13,14. Because the second cleavage-ligation reaction occurs at the 
spacer-repeat junction, the target substrate is variable and this requires some 
flexibility in the LAS-interacting domain of Cas1 for catalyzing the reaction13. 
Probably as a result of this flexibility, in the absence of a proper LAS the Type II 
CRISPR systems can undergo “ectopic spacer integration,” or integration of new 
spacers in the middle of the array19. 
1.3 PROTOSPACER CAPTURE 
Identification of foreign nucleic acids 
CRISPR systems can acquire self-targeting spacers from the host 
chromosome18,36,37, which result in autoimmunity and cell death38-40. To avoid 
this, CRISPR systems employ a variety of mechanisms to bias spacer acquisition 
to foreign genetic elements. 
CRISPR systems utilize the DNA repair machinery of the host, RecBCD in 
Gram negative organisms17,36 and its homologue AddAB in Gram positives	41, for 
the generation of spacer substrates. RecBCD, which binds free ends of dsDNA 
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to perform end resection during homologous recombination, stimulates spacer 
acquisition from double strand breaks. This activity is limited by chi sites, which 
are eight nucleotide sequence motifs that slow RecBCD activity. Because chi 
sites are enriched in the host chromosome relative to phage or plasmid 
genomes, this can serve as a mechanism to constrain spacer acquisition from 
the host genome and differentiate self versus non-self DNA sources36,41. Further, 
the free dsDNA end that is presented to the cell during infection by dsDNA 
phages is exploited by the CRISPR system to preferentially acquire spacers from 
the phage DNA (Figure 1.2.1), since the bacterial chromosome is circular and 
lacks free DNA ends (with the exception of accidental dsDNA breaks, most 
common at the terminus). This also biases the pool of acquired spacers to the 
injected end of the phage genome, which results in the immediate recognition 
and cleavage of the invading DNA at the very beginning of the infection resulting 
in more effective immunity41. Although RecBCD is important for efficient spacer 
acquisition, its degradation products are reported to be ssDNA fragments42,43. 
Given that the in vitro spacer integration studies showed that dsDNA protospacer 
substrates are markedly favored over ssDNA ones10-15,44, it remains unresolved if 
and how RecBCD degradation products could be used for spacer integration 
45,46. Alternatively, it is possible to that the Cas1-Cas2 machinery physically 
associates with RecBCD 47 to either directly uptake degradation products from 
RecBCD 36 or to sample intact dsDNA upstream of RecBCD. Moreover, given 
that spacer acquisition can occur in the absence of RecBCD 36 and AddAB 41, it 
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is clear that alternative pathways exist for spacer generation, which will be an 
interesting area of future study. 
 
Figure 1.2.1. Spacers are acquired during viral DNA injection. 
RecBCD in Gram-negative organisms (or AddAB in Gram-positive organisms) 
generates substrates for spacer acquisition following the injection of viral DNA, 
possibly by producing more invader DNA molecules that contain free ends. 
 
There is also evidence that evolution has tuned CRISPR systems to avoid 
deleterious levels of autoimmunity by limiting the rate of spacer acquisition. In 
laboratory settings, successful acquisition of new spacers against phage is an 
extremely rare event, estimated to occur in only 1 in 107 cells19,48,49. Spacer 
acquisition from the host genome is equally rare and does not pose significant 
fitness costs to the host. However, mutants with increased rates of spacer 
acquisition have been shown to lead to higher levels of toxicity50, suggesting that 
the rate of spacer acquisition has been evolutionary tuned to balance protection 
benefits with autoimmune costs. To mitigate growth rate costs associated with 
autoimmunity, it is also possible for spacer acquisition to be temporally regulated. 
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Indeed, quorum sensing has been implicated as a regulator of CRISPR activity in 
at least two species of bacteria51,52. 
Selection of functional targets 
Only a subset of sequences in foreign genomes can serve as functional 
spacers because of Type-specific targeting requirements. In Types I and II, a 
protospacer-adjacent motif (PAM) located at one of the flanks of the target is 
required to license target cleavage and to prevent the cleavage of the spacer 
sequence in the CRISPR array (repeats lack properly positioned PAMs)53,54. 
While Type III flanking sequence requirements are more flexible	55-57, 
transcription across the target is needed for targeting of the DNA58-61. To ensure 
functional immune responses, CRISPR systems must select protospacers that 
are flanked by the correct PAM or are actively transcribed. 
In Types I and II, the spacer acquisition machinery preferentially samples 
protospacers with functional PAMs. However, the two types employ different 
mechanisms to accomplish this (Figure 1.2.2). In Type I-E, the Cas1-Cas2 
complex has direct, sequence-specific interactions with the PAM that biases 
acquisition to PAM-adjacent protospacers11 (Figure 1.2.2, top). In contrast, the 
Cas1-Cas2 complex from the Type II CRISPR system does not exhibit any PAM 
selectivity13,48. Instead, Cas9’s PAM-interacting domain enforces PAM-specific 
spacer acquisition through direct interactions with the Cas1-Cas2 complex (as 
well as the Type II accessory protein Csn2)48 (Figure 1.2.2, bottom). Spacer 
acquisition has not been observed experimentally for many of the transcription-
dependent Type III CRISPR systems. A small fraction of Type III systems has 
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been shown to harbor reverse transcriptase-Cas1 (RT-Cas1) fusion proteins. 
Indeed, one such system has been observed to preferentially acquire spacers 
from transcribed regions of genomes62,63. While the exact mechanism remains 
unclear, it has been demonstrated that RT-Cas1 fusion proteins can acquire new 
spacers directly from RNA transcripts. These RNA-derived spacers provide a 
mechanism to ensure that their targets are transcribed and can be recognized by 
the Type III RNA-guided nucleases. 
 
Figure 1.2.2. Two mechanisms for selection of functional targets.  
In the type I-E system, Cas1–Cas2 has inherent substrate preference for 
protospacers with a canonical protospacer-adjacent motif (PAM). In type II, the 
PAM-interacting domain of Cas9 (loaded with trans-activating CRISPR RNA 
(tracrRNA), not shown) guides the Cas1–Cas2 complex (as well as the 
accessory protein Csn2) in selecting protospacers. 
 
1.4 PRIMED SPACER ACQUISITION 
Pre-existing spacers can enhance the rate of spacer acquisition in a 
sequence-dependent manner through a process known as primed spacer 
acquisition, or priming (enhanced relative to “naïve acquisition,” in which no full 
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or partially matching spacers are present in the CRISPR array). Priming can 
arise from either perfectly matching spacers or spacers against mutated phages 
(or related phages) with point mutations in the spacer region or PAM. Thus, once 
a host acquires a single spacer against a phage, it becomes more likely to 
subsequently acquire additional spacers from the vicinity of the priming target 
region in the phage genome30,64. This feed-forward cycle is driven by close 
associations and interactions between the spacer acquisition machinery and the 
interference machinery. Indeed, the importance of these associations is 
underscored by the existence of fusion proteins in which interference genes have 
been fused to spacer acquisition genes, like the Cas2-Cas3 fusion protein 
present in Type I-F systems 44,65.  
As of yet, priming has only been observed for Type I CRISPR-Cas 
systems, with the Types I-E and I-F systems as the best studied examples. 
During Type I-E targeting, the crRNA-guided Cascade complex binds to a foreign 
target in a PAM-dependent manner, upon which it recruits the nuclease Cas3 for 
target destruction66. In addition to eliminating the foreign genome, the nuclease 
and helicase activities of Cas3 also drive the production of spacer substrates 
(Figure 1.2.3) 45. Further, in the absence of a proper PAM, Cascade can still bind 
the target and recruit Cas3 in a manner dependent on Cas1-Cas2 67. These 
distinct outcomes arise from alternative conformations adopted by Cascade, in 
particular the Cse1 subunit, upon binding of either a perfect target or a mutated 
target 67-70. In this context, the nuclease domain of Cas3 is inactive and it is 
believed that its helicase activity is used to translocate the Cas1-Cas2 complex 
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along the nearby DNA and drive primed spacer acquisition by the integrase 
complex (Figure 1.2.4) 65,67. 
 
Figure 1.2.3. Primed spacer acquisition against a perfect target.  
The CRISPR RNA (crRNA)-guided CRISPR-associated complex for antiviral 
defence (Cascade) binds to a foreign target in a PAM-dependent manner, and it 
subsequently recruits the nuclease Cas3, which results in the generation of 
suitable substrates for spacer acquisition. 
 
 
Figure 1.2.4. Primed spacer acquisition against a mutated target. 
Imperfect target recognition by Cascade results in an altered conformation of the 
Cse1 subunit. This leads to the recruitment of a nuclease-inactive Cas3 in a 
Cas1–Cas2-dependent manner, which mediates primed spacer acquisition. 
	 15 
 
How these two outcomes relate to one another, and how they are decided 
between, remains unresolved. One possibility is that there are two distinct 
pathways, namely primed spacer acquisition and interference-driven spacer 
acquisition, where there is a threshold for the amount of mutations tolerated to 
either license an interference or priming response. In this case, both responses 
can result in elevated rates of spacer acquisition, though a significantly higher 
boost in the case of interference-driven spacer acquisition 65,71,72. Alternatively, it 
is possible that the CRISPR machinery does not make such strict distinctions 
and rather displays a continuum of activities, ranging from interference to 
priming. In this case, it has been suggested that a single mechanism could 
explain this range of activities 73. 
Primed spacer acquisition allows organisms to defend themselves against 
rapidly evolving phage populations, like phages that evade CRISPR-Cas 
immunity through the introduction of target mutations or related phages with 
conserved but not identical targets64,74,75. Priming can also serve as a 
mechanism to bias spacer acquisition activity to foreign DNA substrates that 
harbor the priming target; i.e., using the molecular memories stored in the 
CRISPR array to differentiate self vs. foreign DNA74. However, the increased rate 
of spacer acquisition resulting from priming poses a dilemma for the host cell: the 
more spacers a CRISPR system acquires, the more likely it is that a spacer with 
a partial match to the host chromosome is incorporated, which would elicit 
primed spacer acquisition from the host genome, resulting in autoimunity72. How 
CRISPR systems balance these costs and benefits remains to be addressed. 
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Whether priming occurs in other CRISPR Types also remains to be determined. 
Similarly to the interaction between Cascade and Cas3 during priming, Cas9 has 
been shown to interact with the Cas1-Cas2 integrase48, an observation that 
opens up the possibility of priming in the Type II CRISPR-Cas immune response. 
For Type III systems, on the other hand, the presence of mismatches between 
the crRNA and the target sequence does not abrogate immunity57, and therefore 
it seems unlikely that primed spacer acquisition can occur as it happens for Type 
I systems. 
1.5 THE ORIGIN OF SPACER SEQUENCES 
CRISPR arrays give unique insight into the genetic material encountered 
and selected against during the course of prokaryotic evolution. As a molecular 
fossil record of past invasions, we can infer not only the genomes that a given 
organism encountered but also in what order. Thus, there has been significant 
interest in analyzing the origin of spacer sequences. Of the spacers that can be 
mapped to sequenced genomes, 80-90% of spacers map to phage genomes 
(Figure 1.3.1). The remainder of mapped spacers match genes associated with 
mobile genetic elements. Surprisingly, though, a vast majority of spacer 
sequences (>90%) originate from unknown sources, comprising the CRISPR 
“dark matter” (Figure 1.3.1)76. 
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Figure 1.3.1. Origin of spacer sequences. 
From bioinformatic analysis of CRISPR arrays in sequenced bacterial genomes, 
the majority of spacers are of unknown origin. But of the fraction of spacers that 
can be mapped, the majority of spacers map to phage genomes, though spacers 
matching plasmids, transposons, and other mobile genetic elements can be 
identified. 
 
For these mysterious spacer sequences, perhaps the most parsimonious 
explanation is that sequence databases are missing a vast diversity of phage and 
MGE sequences. Indeed, sequence analysis has determined that many of these 
unmapped spacer sequences share similar properties with the mapped spacer 
sequences, suggesting that they would map to uncharacterized classes of 
phages and mobile genetic elements77. These dark matter spacers have also 
been found for a large majority of RT-Cas1-derived spacers, suggesting a 
diversity of RNA phages and RNA MGEs that remain to be discovered as well78. 
It is also a possibility that these spacer sequences foreshadow the discovery of 
unexpected sources of nucleic acids. 
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1.6 CONCLUSIONS AND OUTLOOK 
More than ten years after the discovery of CRISPR’s function as a form of 
prokaryotic adaptive immunity, we are fast approaching a comprehensive 
understanding of the molecular mechanisms underlying spacer acquisition. 
Through complementary studies utilizing genetic, biochemical and structural 
approaches, we now have key insights into several major steps of this process, 
from the selection of spacers from foreign genomes to the cleavage-ligation 
reactions of new spacers into the first repeat of the CRISPR array. However, 
gaps in our knowledge exist, particularly at the boundaries of protospacer 
capture and spacer integration. For instance, while it has been demonstrated that 
RecBCD and AddAB are involved in the generation of substrates for spacer 
acquisition, the mechanism of this process is largely unsolved. Further, what kind 
of processing protospacers undergo and how spacer size is regulated remain 
understudied. It is possible that relatively uncharacterized accessory proteins 
(like Cas4 and Csn2) that are associated with spacer acquisition modules could 
play a role in these processes 79. The development of new in vivo and in vitro 
experimental systems will be key to gaining insight into these processes. Indeed, 
one such study has already suggested a role for Cas4 in PAM-dependent 
protospacer processing 33.  
More broadly, it will be interesting to learn how spacer acquisition affects 
other aspects of prokaryotic life. From a cell biological perspective, it will be 
valuable to learn more about the interplay between CRISPR spacer acquisition 
and other host-encoded genes or pathways, like other phage defense 
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mechanisms. From an ecological standpoint, the extent to which spacer 
acquisition occurs in different environmental contexts remains to be explored. 
Finally, metagenomic studies combined with establishment of new in vivo 
systems will be instrumental in understanding how spacer acquisition and 
CRISPR immunity influence the evolution of natural prokaryotic populations in 
physiologically and ecologically relevant contexts. 
The spacer acquisition machinery has begun to be repurposed for 
technological applications. Rather than being used for directed genome editing 
like Cas9, the Cas1-Cas2 machinery has been repurposed as a synthetic 
molecular recorder80. This could be used for storing digital information in 
genomes of bacterial populations81. Additionally, an alternative technique has 
been developed for recording environmental signals encountered by bacterial 
populations82. However, there are currently several factors that limit the utility and 
function of these techniques. Most notably, the low frequency of spacer 
acquisition events makes it impossible to have reliable recording within single 
cells, therefore the current technologies rely on deep sequencing of large 
populations to detect spacer acquisition. It is possible that tools like hyper-Cas9, 
a hyperactive spacer acquisition mutant50, could accelerate both basic and 
technological research in the spacer acquisition field. 
The storage of information is a fundamental aspect of all biological 
systems. CRISPR loci constitute a unique form of biological memory, serving to 
provide heritable and adaptive immunity to prokaryotes. Future research on the 
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biology of CRISPR and spacer acquisition is sure to illuminate our understanding 
of biological memory, prokaryotic evolution, and host-pathogen interactions.  
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CHAPTER 2: CRISPR SYSTEMS OPTIMIZE THEIR IMMUNE RESPONSE BY 
SPECIFYING THE SITE OF SPACER INTEGRATION 
2.1 INTRODUCTION 
Prokaryotes are faced with the perpetual threat of invasion by foreign 
nucleic acids through phage infection and horizontal gene transfer. Clustered 
regularly interspaced short palindromic repeats (CRISPR) loci and CRISPR-
associated (Cas) proteins comprise a heritable and adaptive immune system that 
protects bacteria and archaea from phage2 and plasmid3 infections. 
Immunological memories of these infections are stored in the CRISPR array as 
short spacer sequences that intercalate between repeats and specify the targets 
of CRISPR-Cas immunity. Upon infection, new spacer sequences matching the 
genome of the invading DNA are added to the 5’ end of the CRISPR array2. 
Therefore the CRISPR locus constitutes a molecular fossil record of infections in 
which the first spacer matches the most recent foreign threat, whereas 
downstream spacers correspond to older infections. The CRISPR array of 
repeats and spacers is first transcribed as a long precursor that is processed at 
the repeat sequences to generate small, mature, CRISPR RNAs (crRNAs)21,83,84. 
These associate with and direct RNA-guided Cas nucleases to their targets, 
known as protospacers, in the genome of the invader59,85-87. Cleavage of the viral 
or plasmid target DNA prevents infection3,88. 
Based on the cas gene content, CRISPR-Cas systems are classified into 
six types (I-VI) and 19 subtypes89,90. The polarity of spacer incorporation, i.e. the 
addition of new spacers in the first position of the CRISPR array, is a feature of 
all CRISPR-Cas types studied so far. At the molecular level, the process of 
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spacer acquisition has been mostly studied using the type I-E system from 
Escherichia coli MG165518,74. The Cas1-Cas2 complex from E. coli serves as an 
integrase, catalyzing a nucleophilic attack by the incoming spacer at the leader-
proximal repeat9,15,16. During this concerted cleavage-ligation reaction, the spacer 
is added to the array and the repeat is duplicated simultaneously. The integration 
host factor (IHF) protein directs the addition of spacers into the first position of 
the CRISPR array32. IHF is a histone-like bacterial protein conserved in Gram-
negative organisms that binds an AT-rich region immediately upstream of the 
type I-E CRISPR locus, known as the leader sequence91, creating the proper 
DNA topology for Cas1-Cas2-mediated spacer integration at the first repeat. 
Type II-A CRISPR-Cas systems also display a stringently polarized spacer 
acquisition process2,48. However, most of these systems are present in Gram-
positive bacteria, which lack IHF homologs. In these systems the leader 
sequence is also important for spacer acquisition35, however how the polarity of 
this process is achieved is not clear. More importantly, the physiological 
significance of polarized spacer acquisition, a fundamental feature of CRISPR-
Cas immunity, has not been explored in any CRISPR type. 
Here we studied these fundamental problems of spacer acquisition in the 
type II-A CRISPR-Cas system of Streptococcus pyogenes SF370. Consistent 
with previous studies, we found that deletions of the array-proximal region of the 
leader abolish spacer integration at the leader-end of the CRISPR array. 
However, these deletions do not abolish all spacer acquisition activity. Instead, 
leader mutations result in the erroneous integration of new spacers into the 
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middle of the array, a phenomenon we term ectopic spacer integration. Further 
interrogation revealed that a short and conserved sequence at the 3’ end of the 
leader dictates the site of spacer integration. By uncoupling the requirement for 
the leader during spacer acquisition from its role in positioning spacer integration, 
we were able to investigate the physiological significance of spacer order within 
the CRISPR array. We determined that wild-type, polarized, spacer integration 
provides a fitness advantage over ectopic spacer acquisition due to higher levels 
of host protection provided by spacers in the leader end of the array. This 
increased level of immunity is particularly critical during high titers of phage, like 
those that occur during CRISPR immunization. Our results demonstrate that 
polarized spacer acquisition ensures robust immunity against the latest invader, 
and thereby the most immediate threat to the host. 
2.2 RESULTS 
Deletions within the leader sequence result in ectopic spacer integration. 
The type II-A CRISPR system of S. pyogenes SF370 contains four cas 
genes, a tracrRNA gene, and six spacers (spc1-6) in the CRISPR array21 (Fig. 
2.1.1-A). Immediately upstream of the first repeat there is a 102 bp, AT-rich 
sequence known as the leader91. We previously studied the roles of the different 
cas genes in spacer acquisition by cloning this CRISPR-Cas system on the 
pC194 staphylococcal plasmid and using Staphylococcus aureus RN4220, a 
genetically tractable Gram-positive organism without an endogenous CRISPR-
Cas locus, as the host92. Here we used this experimental set up to investigate the 
function of the leader sequence. We created three strains containing different 
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deletions of 25, 15 or 5 bp at the 3’ end of the leader sequence (Fig. 2.1.1-B). 
Cultures of these mutant strains as well as a wild-type control were infected with 
the staphylococcal lytic phage ΦNM4γ448 during exponential growth, at a 
multiplicity of infection (MOI) of 1 virus per bacterium. After 24 hours, DNA was 
isolated from the surviving cells in each culture and used for PCR analysis of the 
CRISPR locus with primers that amplify the leader-end and thus detect the 
acquisition of new spacers in the first position of the CRISPR array48 (Fig. 2.1.1-
A, blue arrows). All three deletions prevented any detectable insertion of new 
spacers in this position (Fig. 2.1.1-C). This is in agreement with the results 
obtained with the type II-A CRISPR1 locus of Streptococcus thermophilus 
DGCC771035. All of the leader deletion strains tested gave rise to bacteriophage-
resistant mutants, however, which suggested that the CRISPR-Cas immune 
response could still be functional. We hypothesized that spacer acquisition could 
occur in other positions of the CRISPR array and therefore used a different set of 
primers to detect the incorporation of new spacers in any position (Fig. 2.1.1-A, 
green arrows). Surprisingly we were able to observe bona fide spacer acquisition 
events in the middle of the CRISPR array (Fig. 2.1.1-C). Upon sequencing of 
many of these PCR products we determined that, in all three leader deletion 
mutants, the majority of spacer integration events occurred at the fifth repeat, 
positioning the new spacer between spc4 and spc5 (Fig. 2.1.1-D). We term this 
phenomenon, in which new spacers are added into the middle of the array, 
“ectopic” spacer integration. These experiments provide direct, in vivo evidence 
that the leader is involved in specifying the site of spacer integration. 
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Figure 2.1.1. Deletions within the Leader Sequence Result in Ectopic 
Spacer Integration 
(A) Type II-A CRISPR locus from Streptococcus pyogenes SF370. A 102 bp 
leader sequence separates the cas genes from the CRISPR array, which 
contains seven repeats (R1–7) flanking six spacers (spc1-6). Blue and red 
arrows indicate primers used to detect spacer integration at the leader-end 
(polarized) or at the middle of the array (ectopic), respectively. 
(B) Deletions of the leader sequence analyzed in this study. 
(C) PCR-based detection of polarized or ectopic spacer integration using the 
primers described in (A). DNA for PCR was extracted from colonies obtained 
from cultures incubated with (+) or without (−) phage ΦNM4γ4. PCR products 
were separated by agarose gel electrophoresis and stained with ethidium 
bromide. A gel image representative of many PCRs is shown. The size of the 
PCR product reflects the presence (a, “adapted”) or absence (u, “unadapted”) of 
integration of new spacers. 
(D) Position of spacer integration events (marked by the black arrows) after 
Sanger sequencing of PCR products obtained in (C) for cells infected with phage 
carrying different leader sequence deletions. Numbers in table represent totals 
from three replicates. 
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A leader-anchoring sequence specifies the site of integration for new spacers. 
To investigate the leader sequences that specify the site of integration of 
new spacers in more detail, we introduced A-C and G-T transversion mutations 
in the 10 bp at the 3’-end of the leader. We tested two mutants, one with 
mutations in the -5 to -1 region of the leader and one with mutations in the -10 to 
-6 region (Fig. 2.2.1-A). PCR analysis after phage infection with each set of 
primers used in Figure 1 showed that only the -5 to -1 leader mutant resulted in 
ectopic spacer integration (Fig. 2.2.1-B). We have therefore termed this region of 
the leader the “leader-anchoring sequence,” or LAS. This sequence, especially 
the 3’-end GAG, is highly conserved in related type II-A CRISPR systems93 (Fig. 
2.2.2-A). To precisely determine the effect of the LAS on the position of spacer 
integration within the CRISPR locus, we performed next-generation sequencing 
of the PCR products containing the full array obtained after infection of wild-type 
and LAS mutant cultures. We found that while wild-type cells displayed polarized 
spacer integration almost exclusively (>99.999% of new spacers were integrated 
into the first repeat, Fig. 2.2.1-C), LAS mutant bacteria acquired new spacers at 
different positions in the array, with only ~ 0.65 % of the integration events 
occurring at the first repeat and more than 99% at the fifth repeat, positioning the 
new spacer between spc4 and spc5 (Fig. 2.2.1-C). 
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Figure 2.2.1. A Sequence within the Leader Specifies the Site of Spacer 
Integration 
(A) Mutations were introduced at the 3′ end of the leader to define the leader-
anchoring sequence (LAS). (B) Strains containing the leader mutations described 
in (A) were infected with phage ΦNM4γ4 and analyzed by PCR for polarized and 
ectopic spacer integration. (C) Analysis of the site of spacer integration using 
next-generation sequencing. Liquid cultures harboring a wild-type or mutant LAS 
were infected at an MOI of 1, and the DNA isolated from surviving cells at the 
end of infection was used for PCR amplification of the entire array. The expanded 
PCR amplicons were purified from the gel and used for MiSeq next-generation 
sequencing. Bars show the number of normalized reads for the integration of new 
spacers in each possible position of the CRISPR array (marked by the black 
arrows). Mean ± SEM of three replicates are reported. Percentage of spacer 
integration events is indicated above each bar. 
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Figure 2.2.2. The leader anchoring sequence is conserved in related Type 
II-A CRISPR systems.  
(A) Alignment of leader sequences upstream of the first repeat of type II-A 
CRISPR-Cas systems present in different bacteria. Red indicates strong 
conservation, yellow indicates average conservation, green indicates poor 
conservation. (B) Alignment of the 30 nucleotide leader sequence upstream of 
the first repeat of the S. pyogenes CRISPR locus and the spc4 sequence. (C) 
Spacer integration in cells harboring a CRISPR locus in which the sequences of 
spc2 and spc4 were swapped, downstream of a wild-type LAS. (D) Spacer 
integration in cells harboring a CRISPR locus in which the sequences of spc2 
and spc4 were swapped, downstream of a mutant LAS. (E) Spacer integration in 
cells harboring a CRISPR locus in which the sequences of repeat #5 and spc4 
were deleted, downstream of a mutant LAS. 
 
We wondered whether the sequence of spc4 could work as a “pseudo-
LAS” upstream of the fifth repeat that would direct the integration of new spacers 
in the absence of the wild-type LAS upstream of the first repeat. Comparison of 
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the LAS and spc4 sequences indicated that there is very little homology between 
them (Fig. 2.2.2-B). However, it is possible that different sequences could serve 
as anchors for spacer integration. To test this, we switched the positions of spc2 
and spc4 and determined the location of newly acquired spacers. As expected, 
switching the spacers did not affect polarized acquisition in the strain harboring 
the wild-type LAS (Fig. 2.2.2-C). However, all of the LAS-mutant, phage-resistant 
colonies tested contained the new spacer integrated in the third repeat, i.e. 
immediately downstream from the new location of spc4 in this strain (Fig. 2.2.2-
D). In addition, the combination of the LAS mutation and the deletion of spc4 
prevented the detection of spacer integration (Fig. 2.2.2-E). These results 
suggests that in the absence of a proper LAS, other sequences within the type II 
CRISPR array (spc4 in the case of the S. pyogenes CRISPR-Cas system) can 
anchor spacer integration. Altogether our experiments show that short 
sequences immediately upstream of repeats are able to specify the site of spacer 
integration. In particular a short conserved sequence within the CRISPR leader 
immediately upstream of the first repeat, here named the LAS, specifies the 
acquisition of new spacers in the first position of the array with high fidelity. 
The LAS provides a competitive advantage during spacer acquisition. 
Our experiments with LAS mutant cells showed that the CRISPR-Cas 
immune response does not absolutely require the addition of new spacers in the 
first position. In spite of this, all CRISPR-Cas systems studied so far display an 
invariable specificity for spacer integration in this position. We wondered if 
polarized spacer acquisition provided an advantage versus ectopic acquisition. 
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To test this we carried out a series of competition analyses between strains that 
acquire spacers in different positions within the CRISPR array. First we 
performed a pairwise competition assay between strains harboring wild-type or 
mutant LAS. Each of the two naïve strains were grown to exponential phase and 
mixed in a 1:1 ratio. One aliquot of the mixed culture was uninfected as a control, 
while another was infected with phage ΦNM4γ4 at an MOI of 1. The cultures 
were grown for 24 hours and then streaked onto agar plates. DNA from individual 
colonies (originating from cells that survived phage infection) was used for PCR 
and Sanger sequencing to determine the population composition after the 
experiment (16 colonies were analyzed per replicate; 48 colonies total), Fig. 
2.3.1-A). The control showed a 1:1 ratio of wild-type to LAS mutant cells in the 
absence of phage infection, indicating that there is no intrinsic selective 
advantage for any of the strains (16 colonies were analyzed per replicate; 48 
colonies total). In contrast, in the presence of phage only the strain harboring the 
wild-type leader was able to generate resistant colonies, suggesting a strong 
fitness defect for the LAS mutant cells. As expected, all the colonies contained 
new spacers in the first position of the CRISPR array (Fig. 2.3.2-A). This fitness 
defect was also observed during monoculture phage challenges, where the 
survival of cells is measured as the optical density of the culture after addition of 
phage (Fig. 2.3.1-B). In this experiment naïve cells succumb to viral infection and 
the optical density decreases dramatically. However, cultures can regain growth 
upon acquisition of new spacer sequences that direct phage destruction. While 
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cells harboring a wild-type leader sequence restart growing at ~16 hours, LAS 
mutants take ~25 hours to regrow. 
 
Figure 2.3.1. The LAS Confers a Fitness Benefit during CRISPR-Cas 
Immunity 
(A) Analysis of culture composition following direct competition between strains 
harboring the wild-type or mutant LAS. Strains were mixed in a 1:1 ratio and 
infected with phage ΦNM4γ4 at an MOI of 1. Once the infection completed, the 
cultures were streaked onto a plate and colonies were picked to determine their 
LAS by Sanger sequencing (n = 16 per condition per replicate, 96 colonies tested 
in total). Mean + SEM of three replicates are reported. L.d, limit of detection. 
(B) Growth of cultures infected with phage ΦNM4γ4 followed by the 
measurement of optical density at 600 nm (OD600). Cells containing a wild-type or 
mutant LAS were infected, and their OD600 was followed over time. While most 
cells die after infection, a small fraction can acquire new spacers and resume 
growth after viral clearance through CRISPR-Cas immunity. Mean ± SEM (gray 
dotted line) of three replicates are reported. 
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Figure 2.3.2. Deletions of repeat-spacer units within the CRISPR locus shift 
ectopically integrated spacers to the leader-end of the array.  
(A) DNA from mixed cultures incubated with (+) or without (-) phage ΦNM4γ4 
(from Fig. 3A, which contains the average of the three biological replicates for 
each condition reported here) was extracted 24 hours post-infection and used as 
template for PCRbased detection of polarized or ectopic spacer integration as in 
Fig. 1A. (B) DNA from cells harboring a mutant LAS that recovered after phage 
infection (from Fig. 2C) was extracted and used as template for PCR to detect 
expansion of the CRISPR array. In addition to PCR products corresponding to 
expanded, or adapted (a), and unadapted (u) CRISPR loci, a third PCR product 
(d), smaller than the other two, was observed. (C) Next-generation sequencing of 
the DNA rendered sequences corresponding to the smaller band in which the first 
four repeat-spacer units were deleted and the fifth, newly acquired spacer was 
repositioned as the first spacer. 
 
Interestingly, when preparing the samples for next-generation sequencing 
(Fig. 2.2.1-C), we noticed an additional PCR product from the LAS mutant 
sample, smaller than both the naïve and adapted CRISPR arrays present in both 
populations (Fig. 2.3.2-B). Sequencing of these PCR products revealed the 
presence of CRISPR loci that had lost the first four repeat-spacer units to 
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relocate the new spacer in the first position (Fig. 2.3.2-C). This result shows that, 
in the event of ectopic adaptation, there is selective pressure to reposition new 
spacers to the leader-end of the array. Altogether these experiments 
demonstrate that, by enabling the acquisition of new spacers in the first position 
of the CRISPR array, the LAS confers a selective advantage during the CRISPR-
Cas immune response. 
Spacers in the first position of the CRISPR array provide a more robust immune 
response. 
There are at least two possible explanations for the fitness advantage of 
cells harboring a wild-type LAS observed in Figure 3. One scenario is that spc4 
has poor LAS properties and spacer integration at position 5 (in the LAS mutant) 
is less efficient than at the first position (in the wild-type CRISPR locus). Another 
possibility is that spacers integrated into repeat 5 provide a weaker CRISPR 
immune response and take more time to clear the virus and regrow. To explore 
the first scenario, we replaced spc4 with a 30 bp fragment of the leader 
containing the LAS (Fig. 2.4.1-A). In this way the LAS is present upstream of 
both the first and fifth repeats, and there is an optimal LAS for the acquisition of 
spacers in the first or fifth position of the CRISPR array. This set up allowed us to 
perform an “intracellular competition experiment” in which integration at repeat 1 
(the wild-type position) and repeat 5 (the ectopic position) should have similar 
rates. We first corroborated that, in the absence of a wild-type in the LAS 
upstream of the first repeat, the replacement of spc4 for the LAS resulted in the 
exclusive acquisition of new spacers in position 5 (Fig. 2.4.2-A). This also 
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demonstrates that the LAS positively directs spacer acquisition, and therefore 
that the particular LAS mutations that we introduced are not inhibitory for spacer 
incorporation. Next, we infected cells harboring a duplicated LAS and analyzed 
the surviving colonies (Fig. 2.4.1-A). Spacer acquisition events were detectable 
at both leader-repeat junctions, but spacers integrated into the first repeat were 
highly enriched after phage selection (in fact, ectopic spacer integration was 
observed only in 1 of 6 replicates). These data show that polarized spacer 
acquisition is favored over ectopic spacer acquisition even when both integration 
events are mediated by the same, wild-type, LAS. Although it is still possible that 
upstream leader sequences not included in the 30 bp LAS spacer have a minimal 
positive effect on the efficiency of spacer acquisition, this result suggests that the 
selective advantage of the wild-type CRIPSR-Cas system is not due to a low rate 
of spacer incorporation in LAS mutant cells, but rather reflects a difference in the 





Figure 2.4.1. Leader-End Spacers Provide More Robust Immunity than 
Spacers in the Middle of the CRISPR Array 
(A) Analysis of the site of spacer integration in a strain harboring two copies 
of the LAS, upstream of the first and fifth repeat. A culture was infected with 
ΦNM4γ4 at an MOI of 1. The CRISPR array from surviving cells was amplified 
and subjected to Sanger sequencing to determine the position of integration 
(marked by the black arrows) of new spacers. Mean + SEM of six replicates are 
reported. 
(B) Two strains were engineered to test the levels of CRISPR-Cas immunity 
provided by the same spacer sequence located in the first (Position 1 strain) or 
fifth (Position 5 strain) position. In addition, the cas1 gene was mutated to 
prevent the acquisition of new spacers. 
(C) Growth of Position 1 and Position 5 cultures infected with phage ΦNM4γ4 at 
MOI 5 or 50 followed by the measurement of optical density at 600 nm (OD600). 
Mean of three replicates is reported. 
(D) Simulation of CRISPR immunization with Position 1 and Position 5 strains. 
Position 1 or Position 5 cells were diluted with cells lacking CRISPR-Cas in a 
1:10,000 ratio and infected with phage ΦNM4γ4 at an MOI of 1. Cell growth that 
results from CRISPR-Cas immunity was monitored by optical density 
measurements at 600 nm (OD600) for 24 hr. Cells lacking a CRISPR-Cas system 








Figure 2.4.2. Spacer sequences in position 1 provide better CRISPRCas 
immunity than spacers in position 5.  
(A) Spacer acquisition after phage infection of cells containing a mutant LAS 
upstream the first repeat and a wild-type LAS instead of spc4. Surviving cells 
were plated and DNA from colonies was extracted for PCR. Sanger sequence of 
PCR products was used to determine the position of integration (marked by the 
black arrows) of the new spacer. Mean ± SEM of three replicates are reported. 
(B) Efficiency of plaquing (EOP) of the phage ΦNM4γ4 on plates containing cells 
with a targeting spacer in position 1 or 5. To calculate the EOP, the number of 
plaques formed on each of these strains is divided the number of plaques 
obtained using cells without CRISPR-Cas immunity that support full viral 
propagation. EOP = 10-9 is the lower limit of detection of the assay. Mean ± SEM 
of three replicates are reported. (C) Picture of the plates used for panel (B), in 
which 10-fold serial dilution of the phage ΦNM4γ4 were spotted on Position 1 or 
Position 5 cells. The inhibition of growth zone observed in the 10-3 dilution is 
marked. (D) Assay that simulates CRISPR-Cas immunization. Cells already 
immunized (with a spacer targeting the phage ΦNM4γ4) are mixed with an 
excess of non-immune cells at different proportions and infected with phage. The 
time that it takes for each mixed culture to regain growth correlates with the 
amount of immunized cells in the sample. Mean ± SEM (gray dotted line) of three 
replicates is reported. (E) RNA-seq of Position 1 and Position 5 cells showing the 
read count (normalized to total reads) for the crRNA derived from the same 




We examined the second possibility by directly comparing the levels of 
CRISPR immunity provided by polarized and ectopic spacer acquisition. We 
engineered two CRISPR-Cas systems containing the same spacer sequence 
(GTGTTCTCTTCAATCCATTCATCTATTGCT) in two different positions within 
the array (Fig. 2.4.1-B), one mimicking polarized spacer integration (“Position 1”) 
and the other mimicking ectopic spacer integration (“Position 5”). To prevent 
additional immunization events, spacer integration was abrogated in both strains 
by the introduction of an inactivating mutation (E220A) in the Cas1 integrase48,94. 
Both strains were grown to exponential phase and infected with phage ΦNM4γ4 
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at two MOIs, 5 and 50, and growth was monitored by measuring the optical 
density of the cultures (Fig. 2.4.1-C). Position 1 and Position 5 strains exhibited 
comparable levels of immunity at an MOI of 5. In contrast, at an MOI of 50, the 
Position 5 strain showed a severe growth defect. A similar result was obtained 
when phage propagation was measured on plates containing Position 1 or 
Position 5 cells, seeded with 10-fold serial dilutions of the phage ΦNM4γ4 stock. 
Whereas the number of plaques originating from phage escapers (usually 
harboring mutations in the target sequence that makes them refractory to 
CRISPR-Cas immunity 53) were similar for both strains (Fig. 2.4.2-B), Position 5 
plates showed an inhibition of growth zone (most notable at the 10-3 dilution, Fig. 
2.4.2-C), suggestive of some level of phage propagation due to a poor CRISPR-
Cas defense. Altogether these experiments demonstrate that while spacers in 
any location of the array confer some level of immunity to the host, positioning 
the immunity-conferring spacer at the leader-end of the array enables a more 
robust immunity at higher titers of phage. 
CRISPR-Cas immunization is a rare event, calculated to happen only in 1 
in 107 cells of the infected population in our experimental set up48. As a 
consequence of this, most cells in the culture succumb to viral infection, creating 
very high titers of phage. We estimated that the small fraction of cells that is able 
to acquire a new spacer against the phage face an extremely high MOI (on the 
order of 10,000). Given the results obtained in Figure 2.3.1-A, we speculated that 
the position of the targeting spacer in the CRISPR array could be critical for the 
CRISPR immune response under these extreme phage stresses. To test this we 
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developed an assay that simulates the CRISPR immunization process in which a 
small proportion of CRISPR-immune cells (already harboring a phage-targeting 
spacer sequence in either position 1 or position 5) is mixed with a majority of 
non-CRISPR cells that enables exponential phage propagation. In this assay, the 
time at which the culture resumes growth after viral infection is delayed 
proportionately to the fraction of CRISPR-immune cells (Fig. 2.4.2-C). When the 
Position 1 CRISPR-immune strain is tested, growth resumes at ~15 hours (Fig. 
2.4.1-D). In stark contrast, when the Position 5 CRISPR-immune strain is used 
growth resumes at ~20 hours. This pattern mirrors the growth curves produced 
during CRISPR immunization of wild-type and LAS mutant cultures (Fig. 2.3.1-B). 
Together, these results demonstrate that cells in which spacers are integrated 
ectopically suffer a severe growth defect due to compromised immunity.  
2.3 DISCUSSION 
A hallmark feature of CRISPR-Cas systems is the integration of short viral 
spacer sequences into the 5’-end of the CRISPR locus2. However, the 
physiological significance of this highly polarized process has remained 
unknown. Here we studied this problem in the type II-A CRISPR-Cas system of 
S. pyogenes. We found that a short sequence immediately upstream of the first 
CRISPR repeat, which we called the leader-anchoring sequence or LAS, is 
required for the exclusive insertion of spacer sequences in the first position of the 
CRISPR array. Mutations in the LAS result in the integration of new spacers in 
the middle of the array, a phenomenon we called ectopic spacer integration. The 
phenotype of the LAS mutant allowed us to determine the importance of ordered 
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spacer addition during the CRISPR immune response against phage infection. 
We found that polarized spacer integration bestows the host with a competitive 
advantage by positioning the new spacer in the first position of the array, where 
spacers provide more robust CRISPR-Cas immunity. Since the first spacer 
derives from the most recent invader, polarized spacer acquisition allows 
CRISPR-Cas systems to prioritize immunity against the most immediate threat to 
the host. 
Given that Cas9 acts as a single-turnover enzyme27, each crRNA 
molecule that directs the cleavage of one invading phage cannot be re-used to 
cleave a second viral genome. Therefore, the abundance of a targeting crRNA 
could be critical during CRISPR immunization, when cells are challenged by an 
extremely high number of phages. This is because upon infection of a naïve 
bacterial population, the viral titers rise to extraordinary levels due to the initially 
unconstrained transmission of the virus. In this exceptional condition in which a 
few newly-immunized cells are infected by thousands of phages at the same 
time, the abundance of the crRNA guide produced from the new spacer could be 
decisive for the success of the CRISPR-Cas immune response. Higher 
abundance of leader-end crRNAs has been observed in many CRISPR-Cas 
systems21-25. Importantly for our study, the S. pyogenes type II-A CRISPR-Cas 
system produces higher levels of spc1 crRNA than the other crRNAs derived 
from downstream spacers21. Further supporting this scenario, we found that the 
levels of the ΦNM4γ4-targeting crRNA produced from Position 1 is ~2-fold higher 
than when it originates from Position 5 during exponential growth (Fig. 2.4.2-E). 
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We believe that it is conceivable that the same spacer sequence integrated in the 
first or a more downstream position of the CRISPR array could produce different 
levels of mature crRNA due to asymmetric transcription and/or differential 
processing of the crRNA precursor. The molecular mechanisms that lead to the 
uneven distribution of crRNAs, and how small differences in crRNA abundance 
affect the CRISPR immune response, will require further investigation, in type II 
and other CRISPR types. 
While the LAS is critical for the integration of new spacers into the first 
repeat, we have found that the spc4 sequence can also specify the addition of 
spacers into the repeat that follows it. In addition, the mutations inserted in the 
LAS (-1 to -5) do not completely abrogate the integration of spacers in the first 
position of the CRISPR array (Fig. 2.2.1-C). These results suggest that other 
sequences or sequence motifs can perform the LAS function. Moreover, it is 
possible that upstream sequences within the leader could contribute to spacer 
integration, though such sequences were not detectable in a related Type II-A 
CRISPR system (Wei et al.). We propose that the Cas1-Cas2 integrase complex 
samples the nucleotides immediately upstream from the repeat and that the wild-
type LAS provides the optimal sequence for anchoring the complex, biasing its 
activity toward the leader-end of the array. In the type I CRISPR-Cas system, 
binding of IHF to the leader creates the required DNA topology for spacer 
integration at the 5’-end of the array. Given the absence of IHF homologs in 
Gram-positive bacteria (including the host used in our studies, S. aureus) it is 
possible that there are other factors that perform a similar function for type II 
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CRISPR-Cas systems95. Alternatively, the type II Cas1-Cas2 complex could be 
sufficient to catalyze polarized spacer integration without a requirement for 
additional host factors31. Additional work employing biochemical and structural 
techniques will address these questions. 
The prioritization of the CRISPR-Cas immune response against the most 
recent invader has been proposed as a bet-hedging strategy20. This is analogous 
to the mammalian adaptive immune response, where effector T-cell populations 
and antibody titers against a virus are highest immediately post-immunization 
and gradually decrease over time96. By devoting more resources to defending the 
host against the most recent infection, immune systems provide robust protection 
against the infectious agents that are most likely to be present at high titers. This 
is an efficient way to conserve resources while still providing robust immunity 
against the most threatening attackers. For CRISPR-Cas systems, the benefit of 
deprioritizing immunity against past invaders would be two-fold. First, during 
infection of a population that has been immunized in the past, i.e. harboring the 
invader-matching spacer in the middle of the array, transmission of the re-
infecting virus will be immediately contained and viral titers will remain low. In this 
situation the CRISPR-Cas immune response does not need to be at peak levels 
to efficiently protect the population, as shown in Figure 4C in which a spacer in 
position 5 provides full immunity in conditions of low MOI. Second, it has been 
reported that phage mutations in target sequences are highly abundant in viral 
populations and are selected for their ability to enable the escape from CRISPR-
Cas immunity53,97. Therefore there is a high probability that spacers in the middle 
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of the array would not be able to provide immunity against re-infecting, mutated 
phages. In this scenario, maintaining full expression of these spacers would also 
be wasteful. Interestingly, in a scenario of re-infection by high titers of a non-
mutated virus, an old spacer sequence can regain full potency through its 
repositioning as the first spacer sequence (similar to our results of Figure 2.3.2). 
Recombination and deletion within the CRISPR array have been extensively 
described in natural populations97,98 and could represent a functional, rather than 
accidental, feature of CRISPR-Cas loci. Our results ascribe a physiological role 
to the establishment and preservation of the timeline of infection that is a 
hallmark of CRISPR-Cas immune systems and further our understanding of the 
selective pressures that guide the evolution of CRISPR systems. 
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CHAPTER 3: CRISPR SYSTEMS MODULATE LIFESPAN OF 




Bacteria are under constant evolutionary pressure from phage threats. 
CRISPR-Cas systems confer adaptive and heritable immunity to bacteria by 
incorporating short segments of viral DNA, termed spacers, into their genome. 
Spacers are intercalated between semi-palindromic, direct repeats in host loci 
known as CRISPR arrays. Spacers, once transcribed into CRISPR RNAs 
(crRNAs), serve as immunological memories that guide effector nucleases to 
seek and destroy foreign cognate nucleic acids, thereby neutralizing viral threats 
during the interference stage of CRISPR immunity. CRISPR-associated (cas) 
genes encode the protein components of the immune system and are the basis 
by which CRISPR systems are categorized. To date, there are six types and over 
twenty subtypes of CRISPR systems99,100.  
cas1 and cas2 are the most conserved cas genes and can be found in all 
six types100. Together, they form the Cas1-Cas2 integrase, a heterohexameric 
complex that mediates the spacer integration process. New spacers are added 
unidirectionally to the CRISPR array and as a result, the array represents a 
chronological record of past infections. The most recently acquired spacers are 
found at the 5’-end of the array and the most ancestral ones are downstream at 
the 3’-end of the array. The leader is a stretch of DNA that lies immediately 
upstream of the CRISPR array and plays an important role in enforcing polarized 
spacer integration. In Type II CRISPR systems, the Cas1-Cas2 complex makes 
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sequence-specific contacts with the last five nucleotides of the leader, known as 
the leader-anchoring sequence (LAS)5,19,100. This is thought to stabilize the 
integrase complex and enable faster reaction kinetics for spacer integration at 
the leader-end of the array5,13,14,19,100. Spacers at the leader-end of the CRISPR 
array give rise to a more robust immune response relative to downstream 
spacers. Thus, the chronological storage of spacers allows CRISPR systems to 
prioritize resources against the most recent invader19. However, as a 
consequence, addition of new spacers shifts existing spacers further downstream 
within the array, thereby reducing the potency of older spacers. Furthermore, it 
has been shown that an increased number of spacers within a CRISPR array 
weakens the interference provided by individual spacers, likely by a dilution 
effect101. How CRISPR systems balance the benefits of acquiring new spacers 
with the cost of weakening existing spacers has not been explored.  
We hypothesized that natural variation in spacer acquisition rates could 
exist and be a means for CRISPR systems to modulate the lifespan of existing 
spacers. Indeed, our lab previously demonstrated that the rate of spacer 
acquisition could be boosted by artificially introducing mutations in Cas9, the 
hallmark protein of Type II-A CRISPR systems50. Here, we compare the immune 
responses generated by a variety of Type II-A CRISPR systems and show 
significant variation in immunization rates across these systems. CRISPR 
systems that acquire new spacers at a high frequency can rapidly respond to 
new threats, but existing spacers quickly lose their potency. In contrast, CRISPR 
systems that exhibit low-frequency spacer acquisition prioritize the immunity 
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conferred by existing spacers at the cost of a slower uptake of new spacers. We 
found that bacteria have overcome these tradeoffs by harboring multiple CRISPR 
systems that acquire spacers at different rates. Furthermore, we have 
demonstrated that these related CRISPR systems can acquire new spacers 
independently of each other as a result of specific interactions between the 
acquisition machinery and the leader-repeat junction. We propose a model in 
which bacteria can utilize multiple CRISPR systems as a means to form both 
short- and long-term immunological memories to defend against a diversity of 
threats. 
3.2 RESULTS 
Type II-A CRISPR systems exhibit natural variation in their rates of spacer 
acquisition 
Natural variation is a key component of evolution and allows for selective 
pressures to refine the functionality of biological phenomena102. Given that 
previous work from our lab demonstrated that artificially introduced mutations in 
Cas9 could alter the rate of spacer acquisition50, we sought to determine if 
CRISPR systems naturally exhibit variation in their rates of spacer acquisition. 
We reasoned that analysis of closely related CRISPR systems would help to 
minimize confounding variables that could be introduced when comparing more 
evolutionary distant systems. We started by analyzing the spacer content of a 
variety of Type II-A CRISPR systems (N=80)103. Interestingly, we observed a 
wide range in the number of spacers in CRISPR arrays (min: 1, max: 69, mean: 
21.5; Figure 3.1.1-A). This range in the number of spacers suggested that the 
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frequency of spacer addition could vary significantly across different Type II-A 
CRISPR systems. 
 
Figure 3.1.1. Type II-A CRISPR systems exhibit natural variation in their 
rates of spacer acquisition.  
(A) Analysis of the number of spacers in Type II-A CRISPR arrays from 
previously sequenced genomes. (B) PCR analysis of CRISPR arrays at 24 hours 
post infection (MOI 1 pfu/cfu). (C) Growth curves of cell cultures harboring 
different CRISPR systems and infected with phage at MOI 1 pfu/cfu. (D) Analysis 
of bacteriophage-insensitive mutants at 24 hours post infection in a soft-agar 
phage infection assay. 
 
To test this experimentally, we chose four Type II-A CRISPR systems 
originating from streptococcal hosts: Streptococcus pyogenes SF370 
(SpyCRISPR), Streptococcus mutans NN2025 (SmuCRISPR), and 
Streptococcus thermophilus LMD-9 CRISPR01 (SthCRISPR01) and CRISPR03 
(SthCRISPR03). We individually cloned and tested each CRISPR system in 
Staphylococcus aureus RN4220 as done previously19,41,48,50. This experimental 
system allowed us to compare the immune responses of CRISPR systems 
originating from different organisms in a more controlled manner (i.e. infection 
with the same phage, growth in identical media, same host genetic background). 
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In addition, we truncated the CRISPR arrays so that each only contained a single 
spacer in order to minimize spacer-specific effects. We monitored the growth of 
each CRISPR-containing strain after infection with the lytic virus ФNM4γ4 48 at a 
multiplicity of infection (MOI) of 1 pfu/cfu (Figure 3.1.1-B). We observed 
significant variability in the time elapsed before the cells recovered from the 
phage infection suggesting variability in their immune responses. Using PCR-
based analysis of the CRISPR arrays 24 hours post infection, we were able to 
detect spacer acquisition in all four systems with qualitative differences 
consistent with the variability we observed in the growth curves (Figure 3.1.1-C). 
SmuCRISPR and SthCRISPR01 exhibited multiple bands corresponding to up to 
2 or 3 newly added spacers, while SpyCRISPR and SthCRISPR03 only had a 
prominent band corresponding to the addition of a single new spacer. We then 
tested these CRISPR systems using a soft agar spacer acquisition assay, in 
which each colony originates from a single BIM (bacteriophage-insensitive 
mutant). Because all liquid cultures reached peak OD600 values by approximately 
22 hours post infection, we quantified phage-resistant colonies at 24 hours post 
infection. Again, we observed variability (>1 log) in the rates of spacer acquisition 
(Figure 3.1.1-D) and these results were consistent with our liquid phage infection 
assays. To test the generalizability of these results, we performed the same 
assay for each Type II-A CRISPR system using another lytic staphylococcal 
phage, ФNM1γ658. We observed a similar pattern in both liquid and soft agar 
phage infections (Figure 3.1.2-A-C). Notably, while no correlation was observed 
in the soft agar infection with ФNM4γ4 (R2 = 0.09604; Figure 3.1.2-D), the colony 
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count for the soft agar experiment with ФNM1γ6 had a strong correlation with the 
number of spacers naturally found in the array of each system (R2=0.9826; 
Figure 3.1.2-E). Based on these results, we conclude that Type II-A CRISPR 
systems exhibit natural variation in their rates of spacer acquisition and that this 
results in differentially expanded CRISPR arrays in nature. 
 
Figure 3.1.2. Natural variation in the rates of spacer acquisition against 
phage ФNM1γ6.  
(A) PCR analysis of CRISPR arrays at 24 hours post infection (MOI 1 pfu/cfu). 
(B) Growth curves of cell cultures harboring different CRISPR systems and 
infected with phage at MOI 1 pfu/cfu. (C) Analysis of bacteriophage-insensitive 
mutants at 24 hours post infection in a soft-agar phage infection assay. (D&E) 
Comparison of the number of spacers found in WT array with soft-agar BIM 
formation rate for (D) ФNM4γ4 and (E) ФNM1γ6. 
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S. thermophilus LMD-9 utilizes two Type II-A CRISPR systems to form short- and 
long-term immunological memories 
Because adding new spacers and shifting existing spacers further 
downstream within an array weaken their level of immunity conferred19,101, we 
reasoned that CRISPR systems could regulate the potency and lifespan of 
existing spacers by evolutionarily tuning their rate of spacer acquisition. High 
frequency spacer acquisition is beneficial for fast responses to new challenges, 
whereas low frequency spacer acquisition preserves potency of existing spacers 
and retains immunity against recurring threats. Therefore, both high- and low-
frequency systems have costs and benefits, but harboring both varieties would 
allow bacteria to overcome these tradeoffs. We hypothesized that this could be 
the case for Streptococcus thermophilus LMD-9, which harbors two Type II-A 
CRISPR systems that exhibit high- and low-frequency spacer acquisition2,35.  
We developed an experimental system to study the interplay between the 
two Type II-A CRISPR systems of S. thermophilus LMD-9 by introducing them 
into S. aureus RN4220. Upon infection of this double CRISPR-containing strain 
with ФNM4γ4, we observed regrowth of the population approximately 11 hours 
post infection (Figure 3.2.1-A) and detected addition of spacers to both arrays, 
with more spacer addition detectable in the CRISPR01 locus (Figure 3.2.1-B). 
This was consistent with the results from a soft agar infection assay when we 
challenged the strain with ФNM4γ4 and analyzed both CRISPR arrays of each 
colony at 24 hours post infection. We found that 92.49% of the surviving colonies 
had acquired at least one spacer in one of the CRISPR arrays and 87.45% of 
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new spacers were added to CRISPR01 (Figure 3.2.1-C). These results are 
consistent with what has been observed in its native host, suggesting that our 
experimental system is a faithful recapitulation. 
 
Figure 3.2.1. The two Type II-A CRISPR systems of S. thermophilus acquire 
spacers at different rates when expressed in the same cell.  
(A) Growth curves of cell cultures harboring different configurations of CRISPR 
systems from S. thermophilus LMD-9 and infected with phage at MOI 1 pfu/cfu. 
(B) PCR analysis of CRISPR arrays at 24 hours post infection (MOI 1 pfu/cfu). 
(C) Analysis of spacer acquisition in cells harboring the two Type II-A CRISPR 
systems of S. thermophilus at 24 hours post infection in a soft-agar phage 
infection assay. (D) Deep sequencing analysis of spacer acquisition in the two 
CRISPR arrays at an early time point. (E&F) Growth curves of cells harboring two 
sets of overlapping spacers in the two CRISPR systems of S. thermophilus 
infected by phage at different MOIs. 
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To further confirm that the differences in spacer addition we observe is 
due to differences in spacer acquisition activity rather than interference-related 
effects, we amplified and isolated CRISPR loci at 30 minutes post infection using 
a high-sensitivity detection method48. This allowed us to measure spacer 
acquisition independent of interference and survival of the phage infection (lytic 
cycle of ФNM4γ4 is ~45 minutes). Indeed, we observed greater rates of array 
expansion in CRISPR01 relative to CRISPR03 (more abundant species 
corresponding to double and triple spacer addition in CRISPR01; Figure 3.2.2-A). 
Upon high-throughput sequencing and analysis of phage-targeting spacers, we 
observed that the CRISPR01 locus acquired more spacers than CRISPR03 by 
greater than one order of magnitude (Figure 3.2.1-D). We next tested for 
differences in interference by comparing the immunity provided by two different 
sets of spacers for CRISPR01 and CRISPR03. Because each Cas9 has different 
protospacer adjacent motif (PAM) sequence requirements34, it is impossible to 
test identical spacer sequences against the same phage, but we were able to 
design two sets of spacers that share 29/30 bp of homology with overlapping 
PAMs. Indeed, both sets of spacers provided similar protection at various MOIs 
(Figure 3.2.1-E&F). We also tested the rate of escaper phage generation against 
three different spacers for each CRISPR system and found no significant 
difference between the two systems (p = 0.3745; Figure 3.2.2-B). Therefore, we 
conclude that CRISPR01 and CRISPR03 acquire spacers at different rates as a 




Figure 3.2.2. Short- and long-term storage of immunological memories in 
the Type II-A CRISPR systems of S. thermophilus.  
(A) PCR analysis of spacer acquisition in the two CRISPR arrays from an early 
time point phage infection visualized via tapestation. (B) Analysis of phage 
escape rate against three different spacers in each CRISPR system. (C) 
Schematic of CRISPR arrays used to test immunity provided by the same spacer 
upon addition of four additional spacers with random sequences. (D&E) Growth 
curves of cell cultures harboring a phage-targeting spacer in either an ancestral 
or +4 spacers position within the (D) CRISPR01 or (E) CRISPR03 system upon 
infection with phage at MOI 100 or 1 pfu/cfu, respectively. (F) Probabilistic model 
predicting the number of phage infections needed to shift the current spacer 1 to 
position 5 within the CRISPR array for the two CRISPR systems. 
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We hypothesized the different rates of spacer acquisition observed for the 
two Type II-A CRISPR systems allows S. thermophilus to form both short- and 
long-term immunological memories. To support this model, we set out to 
determine whether spacers in the two Type II-A CRISPR systems of 
Streptococcus thermophilus lose potency upon addition of new spacers. For 
each CRISPR system, we tested the same phage-targeting spacer in two 
different arrays, one with the spacer as the first spacer in the array (ancestral) 
and one with four additional non-targeting spacers upstream of the phage-
targeting spacer (+4 spacers) (Figure 3.2.2-C). As predicted, the addition of the 
four new spacers resulted in a weaker immune response for both SthCRISPR01 
and SthCRISPR03 (Figure 3.2.2-D&E). Based on our calculated difference in 
spacer acquisition rates for the two CRISPR systems (Figure 3.2.1-C), we 
generated a probabilistic model to predict how many phage infections it would 
take to reach this point of diminished immunity (Figure 3.2.2-F). Based on this 
model, we predict that while spacers in SthCRISPR01 would become 
significantly weaker after approximately 4 new phage challenges, the spacers 
stored in SthCRISPR03 could maintain their potency for approximately 40 rounds 
of new phage challenges. Taken together, our data support a model in which 
Streptococcus thermophilus can form both long- and short-term immunological 
memories by harboring two CRISPR systems that acquire new spacers at 
different rates. 
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Leader-repeat junction specificity underlies orthogonal spacer storage in S. 
thermophilus 
For the two Type II-A CRISPR systems to acquire spacers at different 
rates within the same cell, the two CRISPR systems have to acquire spacers 
independently of one another. If crosstalk were possible, then the more active 
spacer acquisition machinery could exhibit a dominant phenotype where both 
systems rapidly acquire new spacers. Given their ability to acquire spacers at 
different rates even when we expressed them in the same cell, we speculated 
that the two related CRISPR systems have evolved mechanisms that allow them 
to acquire new spacers independently of one another and avoid crosstalk during 
spacer integration. 
While it has been previously demonstrated that the two systems are able 
to process crRNAs and interfere independently, the possibility of crosstalk during 
spacer acquisition has not yet been addressed. To test our hypothesis, we 
analyzed the spacer sequences inserted into each CRISPR locus in our early 
time point next-generation sequencing experiment. We were able to use PAM 
sequences (CRISPR01: NNAGAAW; CRISPR03: NGGNG34) to assign spacers 
inserted into each array to the spacer integration machinery of each system. We 
found that spacer acquisition was highly accurate for both CRISPR01 and 
CRISPR03 (Figure 3.3.1-A&B). For phage-targeting spacers, both systems were 
greater than 90% accurate (Figure 3.3.1-A; means of 275.103 vs. 0.395 spacers 
for CRISPR01 and 4.460 vs. 0.345 spacers for CRISPR03, mean values in RPM 
for n = 3). Because of the high sensitivity of the PCR-based assay we used, we 
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were also able to detect self-targeting spacer acquisition against the host 
chromosome. For spacers matching the host chromosome, we also observed 
high specificity for both systems (CRISPR01=96.686% and 
CRISPR03=99.306%; Figure 3.3.1-B). This experiment demonstrates that while 
crosstalk is possible between the two systems during spacer acquisition, 
mechanisms have evolved to minimize crosstalk and thereby increase the 



















Figure 3.3.1. Sequences at the leader-repeat junction prevent crosstalk 
between Type II-A CRISPR systems during spacer acquisition.  
(A&B) Deep sequencing analysis of spacer integration accuracy in the two 
CRISPR systems at an early time point against (A) the phage genome and (B) 
the host chromosome. (C) Comparison of the leader-repeat junctions in the two 
Type II-A CRISPR systems of S. thermophilus LMD-9. (D-G) PCR analysis of 
spacer acquisition in arrays with mutations in the leader-repeat junction of the 
(D&E) CRISPR01 and (F&G) CRISPR03 loci (* denotes mutant tracrRNA 
background). 
 
We next sought to probe the mechanisms that enable orthogonal spacer 
acquisition in these two co-existing CRISPR systems. Type II-A CRISPR 
systems have been shown to not require host factors for site-specific spacer 
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integration but rather rely on interactions between the Cas1-Cas2 integrase, the 
leader anchoring sequence (LAS), and the repeat sequence13,14,19. We wondered 
whether differences in the leader-repeat junction of the two CRISPR systems 
were important for reducing crosstalk during spacer acquisition (Figure 3.3.1-C). 
To test determinants of specificity for the spacer acquisition machinery of each 
system, we introduced a variety of plasmids containing mutations in either the 
leader or repeat sequences. To test the importance of the leader, we replaced 
the entire leader sequence with the leader of the other system. For the repeat, 
we swapped bases that differed in the first six and last twelve nucleotides of the 
repeat sequence, as these regions were identified as important for spacer 
integration. We also made compensatory mutations in the tracrRNA to preserve 
base pairing interactions104, which allowed for proper interference from these 
arrays (Figure 3.3.2). Replacement of the SthCRISPR01 leader with the 
sequence from the SthCRISPR03 leader significantly diminished spacer 
acquisition activity (Figure 3.3.1-D). We were then able to narrow down the 
relevant region to the LAS, as just swapping the two nucleotides that differ 
between the LAS’s was sufficient (Figure 3.3.1-E) and reverting those two 
nucleotides in the SthCRISPR03 leader was also sufficient to restore spacer 
acquisition activity in the leader swap construct (Figure 3.3.1-E). Mutations in the 
repeat sequence, however, had little or no effect on spacer acquisition activity 
(Figure 3.3.1-D). These results demonstrate the importance of the leader-repeat 
junction in site-specific spacer integration for SthCRISPR01 and suggest a 
primary role for the LAS in aiding the integrase to discriminate between CRISPR 
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loci. In contrast, we found that the leader sequences were interchangeable for 
SthCRISPR03 (Figure 3.3.1-F). Rather, altering the repeat sequence diminished 
spacer integration activity for SthCRISPR03 (Figure 3.3.1-F). We tested the 
importance of both the 5’ and 3’ ends of the repeat individually, and both 
appeared to be sufficient for reducing spacer integration activity (Figure 3.3.1-G). 
Thus, we conclude that SthCRISPR01 and SthCRISPR03 have evolved distinct 
mechanisms by which they distinguish between CRISPR arrays during spacer 
integration, allowing the two coexisting CRISPR systems to efficiently defend the 
host. 
 
Figure 3.3.2. Compensatory mutations in the tracrRNA enable interference 
with mutated repeat sequences.  
(A&B) Efficiency of plaquing analysis of interference from the native spacer 1 in 




By stably incorporating segments of foreign DNA into arrays, spacer 
acquisition enables a specific and adaptive immune response to foreign threats 
for both the prokaryotic host and its progeny100. However, addition of new 
spacers weakens the immunity provided by existing spacers by pushing them 
further downstream within the array as well as by a dilution effect from the 
increased number of total spacers19,101. We propose that for bacteria that face a 
diverse or rapidly mutating population of phages, evolutionary pressures will 
select for CRISPR systems that acquire new spacers at higher rates. In contrast, 
for bacteria that are faced with recurring infections by similar or related phages, it 
would be more beneficial to preserve the potency of existing spacers by 
acquiring new spacers less frequently. 
Infection of a population of CRISPR-containing cells yields a 
heterogeneous population with a rich diversity of spacer sequences48. Selective 
pressures imposed by the phage population can then shape the distribution of 
spacers in the bacterial population20. It is common for bacteria to harbor multiple 
CRISPR loci (Figure 3.4.1-A). In that scenario, these phage-enforced selective 
pressures can also shape the distribution of spacers across the different CRISPR 
arrays. When the coexisting CRISPR systems belong to different types, it is 
reasonable to speculate that selective advantages conferred by distinct targeting 
mechanisms of the different effector complexes would determine which system 
adapts to a particular threat62. However, it is less clear what advantages would 
be conferred by having multiple CRISPR systems of the same type and even 
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subtype. Here, we have demonstrated that two Type II-A CRISPR systems of 
Streptococcus thermophilus can independently add new spacers at different 
rates to form both short- and long-term immunological memories.  We postulate 
that selective pressures could determine which CRISPR system is used by the 
bacterial population to adapt to new phage threats. For spacers that target a 
broad range of phages or a recurring threat, spacers stored in the low-frequency 
system will have an advantage and will thus be selected for on a population level. 
In contrast, for spacers that respond to a new threat that is not persistent, the 
high-frequency system will be able to rapidly neutralize the threat but potency of 
this spacer will not need to be preserved. Each CRISPR system could also 
benefit the cell differently depending on the ecological niche currently occupied 
by the cell. In niches with high dispersal of phages, a fast-responding CRISPR 
system would be more beneficial due to the diversity of phage likely to be 
encountered. In contrast, in ecological niches with low phage dispersal, a low-
frequency system would be more beneficial because phage infections are more 
likely to be recurring and maintaining the potency of acquired spacers would be 
more beneficial for the population. Our results reveal that intrinsic differences in 
spacer acquisition endows each system with a unique set of benefits and enable 
them to work together to form a robust anti-phage defense system.  
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Figure 3.4.1. Natural variation in rates of spacer acquisition may be 
genetically encoded.  
(A) Analysis of the number of CRISPR loci harbored in various prokaryotic 
genomes. (B) Comparison of BIM formation in the CRISPR system of 
Streptococcus mutans NN2025 harboring either WT or mutated Cas9. (C) 
Comparison of the number of spacers in native CRISPR arrays from Group 1 and 
Group 2 Type II-A CRISPR systems. 
 
We have also demonstrated that the two Type II-A CRISPR systems of S. 
thermophilus have evolved genetic isolation from one another. We have shown 
that specific interactions between the Cas1-Cas2 integrases and the leader-
repeat junctions enable orthogonal storage of spacers. This allows for the two 
Type II-A systems to maintain different rates of spacer uptake and give their 
existing spacers different longevities. CRISPR systems have been categorized 
by their effector cas genes that deal predominantly with the interference phase of 
CRISPR immunity. However, our results reveal that functional differences in 
spacer acquisition can exist among similarly classified CRISPR systems. 
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Previously, our lab demonstrated that by introducing mutations in the cas9 
gene of the Type II-A CRISPR system from Streptococcus pyogenes it was 
possible to increase the rate of spacer acquisition50. Here, we report that natural 
variation in the rates of spacer acquisition also exists among Type II-A CRISPR 
systems. While it remains technically challenging to experimentally address the 
differences in rates of spacer acquisition we observe, we have some hints at 
mechanisms that underlie this variation. For instance, we noticed a leucine 
residue in the 500th amino acid of the Cas9 from the CRISPR system from 
Streptococcus mutans that exhibits a high frequency of spacer acquisition. This 
was similar to a mutation (Cas9K500I) that we previously reported as offering a 
small increase in the rate of spacer acquisition50. We introduced the reciprocal 
mutation into the Streptococcus mutans system (Cas9L500K) and noticed a 
modest decrease in the rate of spacer acquisition (Figure 3.4.1-B), suggesting 
that this is a naturally occurring hyper-Cas9 mutation. For the Streptococcus 
thermophilus CRISPR systems, we noticed that they belong to two separate 
clades of Type II-A CRISPR systems (SthCRISPR01 and SthCRISPR03 belong 
to Group 1 and Group 2, respectively). When we divide our spacer content data 
(Figure 3.1.1-A) by Type II-A Groups, we find that the mean number of spacers 
for Group 1 Type II-A systems is double that of Group 2 (p = 0.0004; Figure 
3.4.1-C). This suggests that these two clades of CRISPR systems have diverged 
for rates of spacer acquisition as well as interactions between Cas1 and the 
leader-repeat junction. Notably, SthCRISPR03 and SpyCRISPR share the most 
sequence homology among this collection of Type II-A CRISPR systems and 
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exhibit comparable rates of spacer acquisition. Together, these observations 
suggest a genetic basis for the differences we observed in spacer acquisition 
rates. As our understanding of the molecular details of spacer acquisition 
increases, it will be interesting for future studies to more directly address the 
molecular basis for the variation we observe in rates of spacer acquisition. 
Similarly, comparative analysis of spacer acquisition in related but functionally 
distinct CRISPR systems could yield a better understanding of the molecular 
basis of CRISPR immunity. 	  
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CHAPTER 4: PERSPECTIVES 
 
CRISPR-Cas systems comprise a genetic immune system to safeguard 
bacteria and archaea from invading threats by storing fragments of foreign DNA 
in CRISPR arrays within the host genome. Once transcribed, these foreign-
derived sequences, called spacers, provide sequence-specificity for CRISPR-
associated (Cas) nucleases to destroy viruses, plasmids, and other potentially 
lethal threats. By stably storing spacers in the genome, CRISPR immunity is both 
adaptive and heritable99,100. 
In my thesis work, I have explored how CRISPR systems store and 
organize their molecular memories of past invaders and the functional 
consequences of this process. By studying the Type II-A CRISPR locus from 
Streptococcus pyogenes, I identified a crucial regulatory region of the CRISPR 
locus that determines the site of spacer integration within the CRISPR array, 
which I termed the leader-anchoring sequence (LAS). The LAS enforces 
polarized addition of spacers to the array such that the chronological order of 
spacer acquisition is preserved. Mutation of the LAS leads to erroneous 
integration of new spacers into the middle of the array. Further, I demonstrated 
that spacers positioned near the LAS provide more robust immunity than spacers 
positioned further downstream. Therefore, CRISPR systems can utilize the 
chronological organization of spacers within the array to prioritize their immune 
resources against the most recent invader19. 
Two complementary studies corroborated my findings through biochemical 
and structural approaches13,14. Wright et al. (2016) demonstrated the importance 
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of the LAS during spacer integration in an in vitro spacer integration assay14. This 
study revealed that improved reaction kinetics on the leader-end of the array, 
presumably from additional contacts made between the spacer integration 
machinery and the LAS, resulted in spacer integration preferentially occurring at 
the leader-end of the array. This was subsequently confirmed by Xiao et al. 
(2017) in their structure of the Cas1-Cas2 complex from a Type II-A system in 
complex with the integration target substrate13. This structure revealed that an α-
helix from Cas1 inserts itself into the minor groove of the leader DNA to make 
direct, sequence-specific contacts with the LAS. Taken together, we now have a 
mechanistic understanding of how spacer acquisition is polarized in Type II 
CRISPR immune systems. 
Less clear, however, is the precise mechanism by which position within a 
CRISPR array affects the level of immunity that it provides. In Chapter 2, I 
demonstrated that altering the position of the same spacer sequence within the 
array modulated the abundance of the corresponding crRNA by two-fold19. While 
this difference is modest, it is possible that other aspects of the CRISPR immune 
response could amplify this difference (i.e. that Cas9 is a single-turnover 
enzyme27). Further experimentation will be needed to fully tease apart this 
mechanism. For example, it would be informative to look at differences in crRNA 
loading into Cas9 that arise from positioning of the spacer within the CRISPR 
array. In addition, little is known about crRNA transcription, processing, and 
loading into Cas9 for Type II-A CRISPR systems, so it remains possible that 
other aspects of these processes are affected by spacer position within the array. 
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In particular, it could be valuable to determine the kinetics of crRNA biogenesis 
after the spacer has been newly integrated into different positions within the 
array. Of course, in vitro reconstitution would provide crucial insights into this 
process. The uneven distribution of crRNA expression has been observed in 
many CRISPR systems and appears to be a general trend for CRISPR immune 
systems19, so it could be informative to look at the generality (or variation) in 
mechanisms that underlie this feature of CRISPR immunity. Notably, a strain 
harboring a natural mutation in its LAS has recently been identified and it was 
confirmed to result in ectopic spacer integration105. Why (and if) a mutation in the 
LAS would be selected for is unclear, but it could imaginably serve as a way to 
bypass strict chronological storage of spacers and give rise to a more complex 
organizational system. 
 While spacer acquisition provides the immediate and significant benefit of 
immunity, it can also impart a cost on the system by weakening the immunity 
provided by existing spacers by shifting them further downstream within the 
array. Also, it has been shown that increasing the absolute number of spacers in 
an array has a detrimental effect on the immunity provided by a single spacer, 
presumably by a dilution effect101. To explore how bacteria deal with this 
conundrum, I examined differences in spacer acquisition rates across a variety of 
related CRISPR systems. I found striking differences in the rates of spacer 
acquisition across Type II-A CRISPR systems, including two systems that coexist 
in Streptococcus thermophilus. By harboring CRISPR systems that acquire new 
spacers at different rates, the bacterial population can store spacers for short- 
	 69 
and long-term utility. Thus, immunological memories are organized not only 
within CRISPR arrays but also across CRISPR arrays to ensure optimal 
immunity. 
On the flip side of spacer acquisition, spacers can also be lost from the 
array28,29, though this process is poorly understood. The rates of spacer loss from 
CRISPR arrays, as well as the mechanistic basis of spacer loss, have not been 
properly studied. However, my work has suggested that spacer loss can be 
functional and selected for. When phage-targeting spacers are downstream in 
the array, deletion of upstream spacers can boost the immunity provided by the 
spacer by repositioning it within the array19. Future studies investigating deletion 
and recombination within and across arrays will provide valuable insights into 
CRISPR evolution and biological memory. 
 Many bacteria harbor multiple CRISPR systems, both of the same type 
and different types. However, many questions remain regarding the functional 
consequences and benefits of these configurations. Further, what advantages 
and disadvantages correspond to the different types of CRISPR systems has not 
been studied. Exploration of the benefits and costs associated with different 
CRISPR systems can shed light on why bacteria harbor multiple types of 
CRISPR systems as well as reasons underlying the diversification of CRISPR 
systems. 
That around half of sequenced bacterial genomes do not contain CRISPR 
systems hints at there being deleterious consequences associated with having a 
CRISPR system, but this has not been fully addressed100. The fact that some 
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CRISPR systems, i.e. Type III loci, can frequently be found without spacer 
acquisition-related genes suggests that the adaptive nature of CRISPR systems 
can itself be detrimental to the cell62,89. This could possibly be due to costs 
associated with autoimmunity resulting from acquisition of spacers against the 
host genome50,106. Another potential cost of having a CRISPR system could be 
limiting beneficial horizontal gene transfer, as we know that a number of 
sequenced spacers map to plasmids and other mobile genetic elements3,76. 
CRISPR-Cas systems, and spacer acquisition in particular, represent a 
unique form of bacterial evolution, in that they provide a quasi-Lamarckian 
mechanism to adapt against genetic threats. What impacts CRISPR immunity 
and spacer acquisition have on the evolution of bacterial genomes remains 
unaddressed. Perhaps most interestingly is that a spacer acquisition event is a 
clear example of a hard selective sweep in a bacterial population. While the initial 
population recovering from a new phage infection is heterogeneous (with many 
spacer sequences in the population48), eventually purifying selection results in 
homogenized populations (uniformity can be observed in downstream spacers 
within the array20). Are beneficial traits unrelated to CRISPR immunity lost 
because of this loss of genetic diversity? Conversely, what traits or genes can 
use this as a means for genetic hitchhiking? If CRISPR immunity does have a 
large impact on shaping genome evolution or limiting genetic diversity in bacterial 
populations, it is tempting to speculate that this could be a reason for bacteria to 
not harbor CRISPR systems (or at least spacer acquisition competent ones) in 
their genomes. 
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More ecological and metagenomic approaches will expand the depth and 
breadth of our understanding of CRISPR biology. A great majority of CRISPR 
studies are conducted under specific sets of idealized conditions that likely do not 
faithfully recapitulate natural environmental contexts (this is not exclusive to 
CRISPR and is a general limitation of many microbiological studies). Studies of 
bacteria-phage interactions using log-phase cultures grown in rich media are not 
likely to accurately reflect the majority of such interactions in nature. For 
instance, the vast majority of bacteria on the planet are in a non-replicative 
state107. This has significant implications for how we view CRISPR biology. For 
instance, it has been experimentally demonstrated that lytic phage programs 
cannot be initiated in dormant cells, but the lytic cycle can resume when the cell 
exits dormancy108. How does this impact spacer acquisition? Is our assessment 
of spacer acquisition as a rare event (~10-7) a gross underestimate? If spacer 
acquisition could still proceed in a non-replicative cell in which phage replication 
is stalled, then perhaps the cell can take advantage of this extra time to acquire 
new spacers. In this case, spacer acquisition could actually be quite common 
within a population. Relatedly, in populations that are exponentially growing, do 
persister cells represent a non-genetic phenotypic subpopulation that acquires 
spacers at higher rates? Generally, how cell metabolism and growth state affect 
CRISPR immunity remains largely unexplored but is a promising area for future 
study. 
Another limitation of current experimental studies of spacer acquisition is 
that the majority ignores lysogeny as an option for cells to gain phage resistance. 
	 72 
Prophages are rampant in sequenced bacterial genomes and can offer protection 
against related phages through superinfection exclusion and against other 
phages by a variety of other phage exclusion mechanisms109. It will be 
informative to study spacer acquisition against lysogeny-competent temperate 
phages. For example, it would be interesting to explore the balance between 
lysogeny-mediated and CRISPR-mediated phage resistance and how 
environmental conditions affect the balance between these two mechanisms. 
Recently, spacer acquisition has been the basis of a variety of new DNA-
based information and memory storage systems110. In addition to this, CRISPR-
Cas systems have been widely repurposed for a variety of technological 
applications, ranging from genome editing111 to point-of-care diagnostics112. 
Altogether, these CRISPR-enabled technological advances have already 
revolutionized the world of biology and medicine, ushering in a new era of 
genome manipulation. But still, the unique and surprising biology of CRISPR 
immune systems in their native microbial world has a wealth of mysteries waiting 
to be unraveled.  
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CHAPTER 5: MATERIALS AND METHODS 
 
Bacterial strains and growth conditions 
Cultivation of S. aureus RN422092 was carried out in brain-heart infusion 
(BHI) or heart infusion (HI) media (BD) at 37°C. When applicable, media was 
supplemented with chloramphenicol (10 µg/mL), erythromycin (10 µg/mL) or 
spectinomycin (250 µg/mL) to ensure maintenance of the pC194-derived113, 
pE194114, or pLZ12-derived115 plasmids, respectively. 
Simulation of CRISPR immunization 
Overnight cultures were diluted 1:100 into fresh BHI supplemented with 
appropriate antibiotics and 5 mM CaCl2. These cultures were then grown to an 
OD600 of 0.2-0.4, upon which they were normalized to OD600 = 0.2. Position 1 and 
Position 5 strains were diluted 1:10,000 into the sensitive strain RN4220 in 
triplicate. The mixed cultures were infected with phage ΦNM4γ4 at an MOI of 1. 
Growth of the cultures was detected measuring OD600 using plate reader. 
Plasmid construction 
The plasmid containing the wild-type Streptococcus pyogenes CRISPR 
(pWJ40) was described elsewhere48. The sequences of all the oligonucleotides 
used in this study are shown in Table S1. DNA sequences obtained by gene 
synthesis (Genewiz, Inc.) are shown in the accompanying Supplemental 
sequences file. Leader deletion 78-102 (pJM13) was constructed by two-piece 
Gibson assembly116 from pWJ40 using the primer pairs JM118-JM91 and JM90-
JM112, respectively. Leader deletions 88-102 (pJM23), 98-102 (pJM25) were 
constructed by one-piece Gibson assembly from pWJ40 using the primer pairs 
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JM118-JM132 and JM118-JM134, respectively. Leader mutation -5 to -1 (pJM28) 
and -10 to -6 (pJM29) were constructed using one-piece Gibson assembly from 
pWJ40 using the primer pairs JM139-JM140 and JM141-JM142, respectively. 
pJM37 (swap of spc2 and spc4) was constructed by inserting the array with BsaI-
compatible overhangs in place of flanking repeats into pDB184 58. The swapped 
array sequence for pJM37 was obtained by gene synthesis. pJM70 (pJM37 with 
LAS mutation) was constructed by two-piece Gibson assembly from pJM37 using 
the primer pairs JM139-JM91 and JM140-JM90. pJM62 (pWJ40 with BsaI-
cloning site for array cloning) was constructed by two-piece Gibson assembly 
from pWJ40 using the primer pairs JM210-JM173 and JM211-JM172.  pJM73 
(insertion of LAS in place of spc4) was constructed by inserting the array with 
BsaI-compatible overhangs in place of flanking repeats into pJM62. The array 
sequence for pJM73 was obtained by gene synthesis. pJM111 (LAS 
mutant Δspc4) was constructed by around-the-horn PCR117 using primers JM318 
and JM319 to remove spacer 4 and one repeat from the pJM28 CRISPR array 
template. pJM74 (pJM73 with LAS mutation) was constructed by two-piece 
Gibson assembly from pJM73 using the primer pairs JM139-JM91 and JM140-
JM90. pJM86 [pJM62 with dCas1 (E220A)] was constructed by two-piece Gibson 
assembly from pJM62 using the primer pairs JM172-PS285 and JM173-PS284. 
pRH253 (pWJ40 with spacer targeting phage ΦNM4γ4) was isolated during an 
on-plate spacer acquisition assay48. pJM87 (Position 5, dCas1, pC194-derived) 
was constructed by inserting the array with BsaI-compatible overhangs in place 
of flanking repeats into pJM86 The array sequence for pJM87 was obtained by 
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gene synthesis. pJM90 (Position 1, dCas1, pC194-derived) was constructed by 
two-piece Gibson assembly from pRH253 using the primer pairs JM172-PS285 
and JM173-PS284.  pJM141 (Position 5, dCas1, pLZ12-derived) and pJM142 
(Position 1, dCas1, pLZ12-derived) were constructed by three-piece Gibson 
assembly from pJM87 and pJM90, respectively, and pLZ12 using the primer 
pairs JM350-JM173, JM351-JM172, and JM352-JM353. 
 The plasmid containing the Streptococcus thermophilus LMD-9 
CRISPR03 was described elsewhere48. The plasmid containing Streptococcus 
thermophilus LMD-9 CRISPR01 was cloned using Gibson assembly using pC194 
and Streptococcus thermophilus LMD-9 genomic DNA as templates with primers 
JM409, JM411, JW155, JW156. The plasmid containing the Streptococcus 
mutans NN2025 CRISPR locus was cloned using Gibson assembly using pC194 
and Streptococcus mutans NN2025 genomic DNA as templates with primers 
JM386, JM389, JM511, JM512. Derivatives of these plasmids were constructed 
using Gibson assembly (details available upon request). Streptococcus 
thermophilus CRISPR arrays with different spacers were constructed using 
Gibson assembly and synthesized DNA constructs purchased from Genewiz. 
Spacer acquisition assay in liquid cultures 
In-liquid spacer acquisition assays were performed using a slightly 
modified method described in 48. Overnight cultures were diluted 1:100 in fresh 
BHI with appropriate antibiotics and 5 mM CaCl2 and grown to OD600 = 0.5. 
Cultures were then infected with phage ΦNM4γ4 at a MOI of 1 phage per 
bacterium, unless otherwise noted, and incubated with shaking at 37°C for 24 
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hours. For Sanger sequencing, cultures were streaked onto a fresh BHI-agar 
plate containing the appropriate antibiotics. Plates were incubated overnight at 
37°C. Single colonies were picked and incubated in lysis buffer (250 mM KCl, 5 
mM MgCl2 50 mM Tris-HCl at pH 9.0, 0.5% Triton X-100) for 20 minutes at 37°C 
and then 98°C for 10 minutes. 1 µl of supernatant was then used as template for 
PCR amplification using TopTaq Master Mix Kit (Qiagen).  
For Streptococcus pyogenes CRISPR spacer acquisition, primers 
JM116/H050 were used for detecting wild-type spacer integration, JM171/JM119 
were used for detecting ectopic spacer integration, and JM116/JM119 were used 
for amplification of the entire array. 
For Streptococcus thermophilus CRISPR spacer acquisition, primers 
JM439/JM440 and H169/H267 were used for CRISPR01 and CRISPR03 
respectively. 
 
Adaptation competition assay 
Overnight cultures were diluted 1:100 into fresh BHI with appropriate 
antibiotics and 5 mM CaCl2 and grown to OD600 = 0.4-0.6. The cultures were then 
normalized by OD600 and mixed in a 1:1 ratio. This mixed culture was then 
infected with phage ΦNM4γ4, in triplicate, at an MOI of 1 for 24 hours, upon 
which the culture was streaked onto a BHI agar plate containing appropriate 
antibiotics. Colonies were subjected to PCR using the primers JM116/JM119 for 
identification of the strain and analysis of spacer integration via Sanger 
sequencing of PCR products. 
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Bacterial growth curves during phage infection 
Phage infections and plate reader growth curves were performed as 
previously described58 with slight modifications. In brief, overnight cultures were 
diluted 1:100 into 2 ml of fresh BHI supplemented with appropriate antibiotics and 
5 mM CaCl2. These cultures were then grown to an OD600 of 0.4-0.6, upon which 
they were infected with phage ΦNM4γ4. To produce plate reader growth curves, 
150 µl of infected cultures, normalized for OD600, was transferred to a 96-well 
plate in triplicate. OD600 measurements were taken every 10 minutes. 
 
Phage titer assay 
Phage titer assays were performed as previously described48. 
 
Detection of spacer integration events using next-generation sequencing 
Overnight cultures were diluted 1:100 in fresh BHI containing the 
appropriate antibiotics. At OD600 = 0.5, the cultures were infected with phage 
ΦNM4γ4 at an MOI of 1. After 24 hours, plasmids were isolated from the cultures 
using the QIAprep Spin Miniprep Kit protocol as previously described48. 100 ng of 
plasmid DNA served as template for PCR amplification using Phusion High-
Fidelity DNA Polymerase (Thermo Scientific) and 6 barcoding primer sets 
(H188/JM257, JM248/JM258, JM249/JM259, JM250/JM260, JM251/JM261, and 
JM252/JM262). After gel extraction and purification of the DNA bands 
corresponding to expanded CRISPR arrays, the DNA was subjected to 
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sequencing by Illumina MiSeq (600 cycles). Reads were filtered by quality score, 
sorted by barcode, and subsequently converted to .txt format using a custom 
Python script that utilized Biopython. Other custom Python scripts were 
employed to create a list of reads, normalized to total number of reads per 
barcode, that met the following criteria: reads must contain 7 spacers and 8 
repeats, the pre-existing spacers must be in the correct order, and the new 
spacer must have at least 15 bp matching the phage genome. 
For early time point deep sequencing, cultures were harvested at 30 
minutes post infection with ΦNM4γ4 at an MOI of 1 and then miniprepped as 
described above using the modified lysostaphin protocol. PCR with Phusion 
polymerase was used to amplify the CRISPR arrays using a special primer set 
designed to amplify low-frequency spacer integration events as done 
previously48. The primers used here were JM472-479. Size selection was done 
using a modified Illumina library preparation protocol as described previously41,48. 
Custom Python scripts and BWA118 were used to analyze the deep sequencing 
data and assign PAMs to unique spacer reads based on genome alignment. 
 
Preparation of electrocompetent S. aureus cells 
Electrocompetent S. aureus cells were prepared and transformed with 
DNA using a previously described method58, with the exception of using BHI 
medium instead of TSB medium. 
 
Mathematical modeling of dual CRISPR system spacer acquisition 
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 A probabilistic model was generated using a custom Python script which 
assumed a 9:1 spacer acquisition ratio for CRISPR01:CRISPR03. The average 
values over one hundred iterations was used for the model presented here. 
 
 
Leader sequence alignments 
Related type II-A CRISPR systems were selected based on previous work 
that classified these systems93. Multiple sequence alignment was performed and 
visualized using T-Coffee119. 
 
Bioinformatic analysis of Type II-A CRISPR systems 
The databases entitled CRISPRdb (http://crispr.i2bc.paris-
saclay.fr/crispr/)120 and CRISPI (http://crispi.genouest.org/)121 were used to 
collect data on CRISPR array length and other characteristics of CRISPR 
systems. The list of CRISPR systems was compiled based on a previous 
analysis of Type II-A CRISPR systems103. 
 
Total RNA extraction 
Total RNA was extracted as described in Jiang et al. 2016122 with minor 
modifications. Briefly, 6 ml of S. aureus culture was pelleted and was 
resuspended in 1 ml of  TRIzol (Thermo Fisher Scientific). The cell suspension 
was transferred to 2 ml-tubes pre-filled with 0.25 cm3 of 0.1 mm glass beads on 
ice. Cells were disrupted twice at 4°C, using MiniBeadbeater-1 (BioSpec 
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Products) at an intensity setting of 42 for 30 seconds. 200 µl of chloroform was 
added to the mixture and the remainder of the RNA extraction was carried out 
according to the Trizol manufacturer’s instructions. 
 
Small RNA library preparation and next-generation sequencing of RNA 
Small RNA libraries were prepared with the TruSeq Small RNA Library 
Preparation Kit (Illumina) using 2 µg of total RNA extracted from cultures at 
OD600 = 0.5. Reverse transcribed and PCR-amplified RNA species between 30 
and 55 nt were purified by gel extraction and ethanol precipitation. The purified 
DNA was subjected to next-generation sequencing by Illumina MiSeq (150 
cycles). Reads were sorted by index and converted to .txt format using a custom 
Python script that utilized Biopython. Other custom Python scripts were used 
analyze crRNA abundance.  
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